Selective TREG stimulator RUR20kD-IL-2 and related compositions
By developing a selective Treg stimulant RUR20kD-IL-2 composition and using a PEGylated IL-2 mixture for low-dose subcutaneous administration, the efficacy and side effects of existing IL-2 therapies have been addressed. This approach achieves selective activation and expansion of regulatory T cells, effectively treating autoimmune diseases.
Patent Information
- Application Number
- CN201980034052.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2019-05-20
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2039-05-20
AI Technical Summary
Existing treatments for autoimmune diseases are ineffective, have significant side effects, poor patient compliance, and are difficult to balance regulatory T cells and effector T cells. Conventional IL-2 therapy requires frequent injections and carries the risk of adverse events.
A selective Treg stimulant RUR20kD-IL-2 composition was developed by stably covalently conjugating IL-2 with 20kDa polyethylene glycol (PEG) to form a PEGylated IL-2 mixture in a specific ratio for low-dose subcutaneous administration to selectively restore Treg homeostasis and reduce the impact on other immune cells.
It achieves selective activation and expansion of regulatory T cells at low doses, maintains long-term immune balance, reduces side effects, improves patient compliance, and effectively treats autoimmune diseases.
Smart Images

Figure CN112399859B_ABST
Abstract
Description
[0001] The present application relates to long-acting interleukin-2 receptor (IL-2R) agonist Treg stimulator compositions that selectively increase the number and activation of regulatory T cells relative to effector T cells, and to methods of using these Treg stimulator compositions to treat autoimmune and inflammatory diseases and / or other conditions responsive to Treg stimulation therapy. Specifically, the present application relates to a selective Treg stimulator composition RUR 20kD -IL-2 and related compositions, methods of preparation, formulations and uses thereof RUR 20kD - Methods for use of IL-2 and related compositions in the treatment of autoimmune diseases and inflammatory disorders.
[0002] The immune system is the body's main line of defense against invading infectious organisms. In a normally functioning immune system, no immune response occurs against self-antigens; this is called self-tolerance. Autoimmune diseases occur when the body's own immune system attacks body tissues due to a loss of tolerance to self-antigens (Dejaco, C., et al. , Immunology . 2006; 117(3): 289-300). In subjects with autoimmune diseases, antigen-specific cytotoxic T cells or autoantibodies destroy body tissues, with the accompanying inflammation causing disability and, in some cases, death. Autoimmune diseases are a heterogeneous group of disorders with a wide range of symptoms that affect approximately 6% of the population (Siatskas, C., et al. ,Curr Gene Ther . 2006; 6(1): 45-58). Although the clinical features of autoimmune diseases vary greatly, the immune-mediated mechanisms are associated with the generation of an adaptive immune response against the target antigen (Kuby, J., 1994: Autoimmunity. Immunology, 2nd edition, p 445-467. WH Freeman and Company, New York).
[0003] Although various conventional treatments such as corticosteroids, cyclophosphamide, azathioprine, and methotrexate are modestly effective in some patients with autoimmune diseases, they are not consistently effective and are associated with side effects and toxicity (Jantunen, E., et al. , Bone Marrow Transplant . 2000; 25(4): 351-6). Such conventional approaches fail to address the underlying pathology associated with autoreactive immunity.
[0004] In view of the recent progress in the understanding of the pathophysiology of autoimmune diseases, potential new therapies focusing on cellular or molecular targets have been developed and are currently being evaluated. Although the cause of autoimmune diseases is unknown, it is believed that it is caused by genetic factors, improper immune regulation, and potential interactions between hormones and environmental factors. Various mechanisms that induce autoimmune diseases have been proposed, including chelated antigens, molecular mimicry, irregular expression of MHC class II molecules, cytokine imbalance, dysfunction of idiotype network regulatory pathways, general regulatory T cell defects and polyclonal B cell activation (Kuby, 1994, supra). Several methods for treating autoimmune diseases have been studied, including B cell depletion, anti-cytokine therapy and stem cell therapy, but these methods are insufficient in terms of efficacy, safety and / or undesirable side effects. Conventional therapies for the treatment of autoimmune diseases function by suppressing the overall immune system, resulting in significant risks of infection and other serious side effects. Therefore, additional treatments are still needed to provide improved combinations of efficacy, safety and / or tolerance for the treatment of autoimmune diseases.
[0005] For many years, the effect of IL-2 in autoimmune response has been established as a proinflammatory cytokine. However, more recent studies have shown that IL-2 can play a protective role in chronic autoimmune inflammation under certain conditions. Specifically, the balance of the destruction between regulatory T cells (Treg) and effector T cells (Teff) has been identified as a common feature of various autoimmune diseases, wherein the balance of this destruction is considered to be affected by homeostatic cytokines, such as IL-2. Due to its pharmacokinetic profile, the use of unmodified IL-2 for autoimmune therapy requires frequent daily or every other day administration, which is often accompanied by painful injection site reactions. In addition, due to discomfort and inconvenience, the necessity of frequent injections is often accompanied by poor patient compliance. The long-term repeated administration of IL-2 is also accompanied by the risk of unwanted pleiotropy and systemic activity of IL-2 and the associated risks and adverse effects. In addition, due to limited treatment window, using unmodified IL-2 to achieve immune homeostasis and maintain the desired Treg / Teff balance can prove challenging in an extended period of time, if not impossible to achieve. In addition, the narrow treatment boundary of its autoimmune disease therapy needs to apply extremely low doses of IL-2, thus adversely affecting its effectiveness. Although low-dose IL-2 can be used to stimulate Treg to obtain some clinical benefits, adverse events are dose-limiting, and Treg increase is moderate and short-term. For example, unmodified IL-2 is used for autoimmune disease therapy to induce the undesirable increase of IL-5 and the subsequent rise of eosinophil levels, which can cause inflammation. Therefore, it is still necessary to selectively regulate the medicament of IL-2 signaling in a balanced manner to promote the disease alleviation of regulatory T cells and effector T cell activity in various autoimmune diseases.
[0006] Specific autoimmune diseases have potential causes, including impaired IL-2 production and / or regulatory T cell defects, which have been implicated as immunological mechanisms prior to disease onset. There remains a need for alternative and more effective therapeutic compositions and treatment regimens to effectively alleviate autoimmune symptoms, improve quality of life, and preferably provide prolonged relief in various autoimmune diseases. The present disclosure addresses the limited availability and associated shortcomings of current options for treating chronic autoimmune diseases.
[0007] Overview
[0008] The present disclosure is based on the selective Treg stimulator RUR 20kD - Discovery of IL-2 and related compositions. RUR 20kD-IL-2 selective Treg stimulator compositions are mixtures of IL-2-PEG conjugates with defined heterogeneity. They are intended for low-dose subcutaneous administration to selectively restore Treg homeostasis with minimal effects on other immune cells. RUR 20kD -IL-2 selective Treg stimulator composition is a conjugate mixture comprising recombinant human interleukin-2 (rhIL-2, and in particular, aldesleukin amino acid sequence without additional amino acid mutations or substitutions) stably covalently conjugated to a 20kDa polyethylene glycol (PEG) moiety, wherein the mixture has a defined fraction, each IL-2 moiety having a specific degree of PEGylation. The composition of the present disclosure comprises a selected mixture of IL-2 PEG conjugates, having a defined fraction of mainly di-PEGylated and tri-PEGylated IL-2, and a defined fraction of less mono-PEGylated IL-2 and / or tetra- or higher PEGylated IL-2. Specifically, the composition of the present disclosure provides a selective Treg stimulator RUR 20kD -IL-2 and related compositions, methods of preparation, formulations and uses thereof RUR 20kD - IL-2 and related compositions for use in methods of treating autoimmune diseases and inflammatory conditions. RUR 20kD -IL-2 compositions induce sustained responses in immunoinflammatory diseases by activating and expanding antigen-specific T regulatory cells. 20kD -IL-2 compositions for treating autoimmune diseases may provide a means of selectively restoring Treg homeostasis with minimal effects on conventional T cell function, thereby providing an alternative and / or improved approach to alleviating these conditions.
[0009] BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1A and 1B is a representative reverse phase HPLC graph, which illustrates RUR 20kD - General composition of IL-2 compositions, the preparation of which is described in Examples 1 and 1 A. Moving from left to right along the x-axis (elution time, minutes), the purified conjugate composition contains primarily di-PEGylated and tri-PEGylated rIL-2.
[0011] Figure 2 It is the amino acid sequence of aldesleukin (125-L-serine-2-133 interleukin 2, a recombinant non-glycosylated interleukin-2 expressed in Escherichia coli).
[0012] Figure 3A and 3B This indicates that a single dose of RUR was administered in mice as described in Example 2. 20kD-IL-2 composition in the blood ( Figure 3A ) and spleen ( Figure 3B ) is a graph showing the results of pharmacodynamic analysis of mouse Tregs.
[0013] Figure 4A , 4B and 4C are graphs showing a single dose of RUR administered in mice as described in Example 2. 20kD -Graph showing the levels of NK cells, CD4 T cells and CD8 T cells in the blood respectively after IL-2 combination.
[0014] Figure 5A and 5B A single dose of RUR was administered in mice as described in Example 2. 20kD - Graph of Treg function and activity as measured by mean fluorescence intensity (MFI) of CD25 and Foxp3 after IL-2 combination.
[0015] 6A-D are graphs of splenic Tregs isolated from vehicle-treated mice at days 1 and 4 in an in vitro Treg suppression assay as described in Example 3. FIG.
[0016] Figure 7 is a graph showing the relative suppressive capacity of isolated Tregs cultured at a 1:2 ratio with Tcon (conventional T cells) evaluated over time as described in Example 3.
[0017] Fig. 8A and 8B Indicates the use of RUR 20kD - The extent of ear swelling in mice treated with IL-2 composition; This study was conducted to evaluate the 20kD - The ability of IL-2 administered Tregs to suppress T-cell antigen-driven inflammation in a mouse model of delayed type hypersensitivity (DTH), as described in Example 4.
[0018] Fig.9A -C is a single dose of RUR administered in cynomolgus monkeys as described in Example 5 20kD -Graph of Treg levels in blood (CD4, CD25, FOXP3 respectively) after IL-2 combination.
[0019] Fig. 10A and B are graphs showing administration of RUR in mice as described in Example 7 20kD - Graph showing the results of pharmacodynamic analysis of mouse Tregs following administration of IL-2 compositions or unmodified IL-2 (aldesleukin).
[0020] Fig.11When evaluated in a mouse model of systemic lupus erythematosus (SLE), administration of RUR 20kD - Graph of urine protein levels (g / L) over time in mice treated with IL-2 composition (0.3 mg / kg).
[0021] Fig.12 is the RUR of various doses administered at a single time. 20kD -CD4+FoxP3+CD25 in peripheral blood samples over time (days) after IL-2 combination 亮 A graph showing the results of pharmacodynamic analysis of Treg (number of cells / μL).
[0022] Fig.13 is the RUR of various dose amounts administered to human subjects as described in Example 10. 20kD - Graph showing the results of pharmacodynamic analysis of total CD4+FoxP3+CD25+ Tregs (cells / μL) in peripheral blood samples over time (days) after IL-2 composition.
[0023] 14A-D are RURs of various doses of a single dose administered to human subjects as described in Example 10. 20kD Figures 14C and 14D are graphs illustrating the RUR of various doses of Tcon cells, CD4+ (Figure 14A) and CD8+ Tcon cells (Figure 14B) in peripheral blood samples over time (days) after administration of a single IL-2 composition to a human subject. 20kD - Graph showing the number of CD8+ T cells (cells / μL) and the number of Ki67+CD8+ T cells (expressed as percentage of CD8) in peripheral blood samples over time (days) after IL-2 composition.
[0024] Fig.15A , 15B Figure 2 is a graph of CD25 bright+ / FoxP3+ Treg counted using flow cytometry. 20kD - Whole blood was collected from human subjects at various time points after IL-2 treatment, as described in Example 10. Fig.15A The median peak effect of each dose on the number of CD25 bright+ / FoxP3+ Tregs (cells / μl) is shown. Fig. 15B The absolute number of CD25 bright+ / FoxP3+ Tregs over time (days) after treatment is presented.
[0025] Fig.16A , 16BFigure 2 is a graph of CD4+ and CD8+ T cells counted using flow cytometry, respectively. 20kD - Whole blood was collected from human subjects at various time points after IL-2 treatment, as described in Example 10. Results are presented as the proportion (%) of each cell population and the fold change calculated based on pre-treatment values.
[0026] Fig.17A , 17B is the dose-response ratio of Treg to Tcon counted using flow cytometry ( Fig.17A ) and CD25 bright+ / FoxP3+ Treg and CD8+ T cells ( Fig. 17B ) . RUR before treatment and with a single administration of various doses of 20kD - Whole blood was collected from human subjects at various time points after IL-2 treatment, as described in Example 10. Results are presented as ratios of the proportions (%) of each cell population and fold changes calculated based on pre-treatment values. Tcon cells are CD8+ T cells.
[0027] Details
[0028] The present disclosure provides a selective Treg stimulator composition comprising RUR 20kD -IL-2 embodiments and related compositions. In general, the chemically modified IL-2 conjugate compositions provided herein are characterized by having a specific and dominant number of branched polyethylene glycol moieties that are stably covalently attached to IL-2 via their amino groups. The compositions provided herein comprise a selected mixture of IL-2 PEG conjugates having a defined fraction of predominantly di-PEGylated and tri-PEGylated IL-2, and a defined fraction of less mono-PEGylated IL-2 and / or tetra- or higher-PEGylated IL-2.
[0029] In one aspect, the present disclosure provides a composition comprising a PEGylated IL-2 conjugate having the structure:
[0030]
[0031]
[0032] in:
[0033] IL-2 is interleukin-2;
[0034] n is independently at each occurrence an integer from about 3 to about 4,000.
[0035] In a specific embodiment of the composition, the IL-2 is aldesleukin. In a specific embodiment of the composition, the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons. In a further specific embodiment of the composition, the PEGylated IL-2 conjugate of the composition has a PEG moiety attached at lysine 31.
[0036] In one aspect, provided herein is a composition comprising a conjugate of the formula:
[0037]
[0038] wherein IL-2 is interleukin-2, n is an integer from about 3 to about 4000, and n′ is 2 and 3.
[0039] The polymer portion of formula (I) is also referred to as 1,3-bis(methoxypoly(ethylene glycol) MW 10,000 carbamoyl)-2-propoxy)-4-butanoyl (up to and including the carbonyl group covalently attached to the amino nitrogen of the IL-2 portion). The mixture composition according to formula (I) is generally referred to herein as RUR-IL2, which covers a range of PEG sizes. In addition to about 3 to about 4000, illustrative ranges of n include, for example, about 5-2000, or about 10-1000, or about 10-750, or about 10-500, or about 10-400, or about 10-300, or about 10-250, or about 20-250. In some embodiments, n averages about 226.
[0040] In another aspect, provided herein is a composition of the formula:
[0041]
[0042] wherein IL-2 is interleukin-2, n is an integer from about 3 to about 4000, and n′ is 1, 2, and 3.
[0043] In some embodiments, the selective Treg stimulator composition of Formula I comprises an IL-2R stably covalently attached to a branched polyethylene glycol moiety, wherein the number of branched PEG moieties per IL-2 moiety (degree of PEGylation) is a distribution of major 2- and 3-mers (di- and tri-PEGylated) in the mixture, with a minor fraction comprising 1-mers (mono-PEGylated) and 4-mers (tetra-PEGylated). Thus, in some embodiments, the minor fraction in the composition according to Formula I will include conjugates wherein n' is 1, 4, 5 or higher, but not greater than 11.
[0044] For example, in one embodiment, the selective Treg stimulator composition is encompassed by the following structure:
[0045] wherein IL-2 is one of the amino acid residues of IL-2, and "NH" shown in structure (Ib) is the amino group of said IL-2 residue; wherein "n" is an integer from about 3 to about 4000; and n' is 2 and 3.
[0046] In some embodiments, provided herein is a RUR 20kD -IL-2 selective Treg stimulator compositions and related compositions. These compositions comprise IL-2 conjugates with separate covalent PEG attachments having a total nominal molecular weight of about 20kD, as described herein. Preferably, the IL-2 portion is aldesleukin. These compositions further comprise a selected mixture of IL-2 PEG conjugates having a defined fraction of predominantly di-PEGylated and tri-PEGylated IL-2, and a defined fraction of less mono-PEGylated IL-2 and / or tetra- or higher PEGylated IL-2. RUR 20kD Specific formulations of IL-2 compositions are described below and throughout the application. As used herein, the RUR of Formulation A 20kD - Composition of IL-2, RUR of Formulation B 20kD - Composition of IL-2, RUR of Formulation C 20kD - Composition of IL-2, RUR of Formulation D 20kD - Composition of IL-2 and / or RUR of Formulation E 20kD -IL-2 Combinations Represent Selective Treg Stimulators RUR 20kD - Certain embodiments of IL-2 and related compositions, and in these embodiments, the IL-2 moiety is aldesleukin (as described herein). Optionally, these compositions comprise a pharmaceutically acceptable salt thereof.
[0047] In one embodiment, the present invention provides a RUR of formula A 20kD -IL-2 composition, wherein on a molar basis, the composition comprises about 5 mol % or less of mono-PEGylated IL-2 conjugates, and about 28 mol % to about 60 mol % of di-PEGylated IL-2 conjugates, and about 24 mol % to about 65 mol % of tri-PEGylated IL-2 conjugates, and about 12 mol % or less of higher PEGylated IL-2 conjugates, and wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons. Preferably, the RUR of formula A 20kD The compositions of IL-2 contain 80 mol % or more of combined di- and tri-PEGylated IL-2 conjugates.
[0048] In one embodiment, the present invention provides a RUR of Formulation B 20kD -IL-2 composition, wherein on a molar basis, the composition comprises about 2.5 to about 4.5 mol % of mono-PEGylated IL-2 conjugates, and about 35 to about 50 mol % of di-PEGylated IL-2 conjugates, and about 38 to about 46 mol % of tri-PEGylated IL-2 conjugates, and about 3 to about 10 mol % of higher PEGylated IL-2 conjugates, and wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons. Preferably, the RUR of formula B 20kD The composition of -IL-2 comprises about 80 to 95 mol % of the combined total amount of di-PEGylated and tri-PEGylated IL-2 conjugates.
[0049] In one embodiment, the present invention provides a RUR of Formulation C 20kD -IL-2 composition, wherein on a molar basis, the composition comprises about 2.8 to about 3.8 mol % of mono-PEGylated IL-2 conjugates, and about 44 to about 48 mol % of di-PEGylated IL-2 conjugates, and about 41 to about 44 mol % of tri-PEGylated IL-2 conjugates, and about 7 to about 9 mol % of higher PEGylated IL-2 conjugates, and wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons. Preferably, the RUR of Formulation C 20kD The composition of -IL-2 comprises about 87 to 90 mol % of the combined total amount of di-PEGylated and tri-PEGylated IL-2 conjugates.
[0050] In one embodiment, provided herein is a RUR of Formulation D 20kD -IL-2 composition, wherein on a molar basis, the composition comprises about 2.8 to about 3.8 mol % of mono-PEGylated IL-2 conjugates, and about 44 to about 48 mol % of di-PEGylated IL-2 conjugates, and about 41 to about 44 mol % of tri-PEGylated IL-2 conjugates, and about 7 to about 9 mol % of higher PEGylated IL-2 conjugates, and wherein the composition comprises a mixture of mono-PEGylated IL-2 conjugates having a PEG moiety attached at one of lysines K7 or K8 or K31 or K75, and wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons. Preferably, the RUR of Formula D 20kD The composition of -IL-2 comprises about 87 to 90 mol % of the combined total amount of di-PEGylated and tri-PEGylated IL-2 conjugates.
[0051] In one embodiment, provided herein is a RUR of Formulation E 20kD -IL-2 composition, wherein on a molar basis, the composition comprises about 2.8 to about 3.8 mol % of a mono-PEGylated IL-2 conjugate, and about 44 to about 48 mol % of a di-PEGylated IL-2 conjugate, and about 41 to about 44 mol % of a tri-PEGylated IL-2 conjugate, and about 7 to about 9 mol % of a higher PEGylated IL-2 conjugate, and wherein the composition comprises a mono-PEGylated IL-2 conjugate having a PEG moiety attached at lysine K7, wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons. Preferably, the RUR of Formulation E 20kD The composition of -IL-2 comprises about 87 to 90 mol % of the combined total amount of di-PEGylated and tri-PEGylated IL-2 conjugates.
[0052] As used herein, “RUR 20kD -IL-2 and related compositions" may refer to RUR according to formula A 20kD - IL-2 and / or RUR of Formulation B 20kD - RUR of IL-2 and / or Formula C 20kD - IL-2 and / or RUR of Formula D 20kD - RUR of IL-2 and / or Formula E 20kD -IL-2 and / or pharmaceutically acceptable salts thereof. The formulations of Example 1 and / or Example 1A are "RUR 20kD -IL-2 and related compositions" are non-limiting examples.
[0053] Further embodiments of the selective Treg stimulator compositions provided herein:
[0054] The compositions provided herein can include conjugates wherein n is equal to 2, for example, di-PEGylated conjugates wherein two branched polyethylene glycol polymers (each having a 1,3-bis(methoxypoly(ethylene glycol)) shown above) 10kDIn some embodiments, the di-PEGylated IL-2 conjugates of the composition may be attached at the same relative position for substantially all di-PEGylated IL-2 conjugates in the composition. Alternatively, the di-PEGylated conjugates may comprise a mixture of di-PEGylated conjugates, such as a mixture of di-PEGylated conjugates in which attachment of the branched polyethylene glycol moiety occurs at two sites on IL-2, wherein the specific attachment site is not the same for all di-PEGylated IL-2 conjugates contained in the composition. Thus, such di-PEGylated compositions are homogeneous in terms of the degree of PEGylation, in particular the number of attached branched PEG moieties (e.g., 2-mers), but are heterogeneous in terms of the position of PEG attachment on IL-2, and in this case represent positional isomers of PEG attachment.
[0055] The composition may also include a single conjugate in which n is equal to 3, for example, a tri-PEGylated conjugate in which three branched polyethylene glycol moieties are attached at the same relative position for substantially all IL-2 conjugates in the composition. Alternatively, the tri-PEGylated conjugate may include a mixture of tri-PEGylated conjugates, for example, a mixture of tri-PEGylated conjugates in which the attachment sites of the branched polyethylene glycol moieties are present at different sites on IL-2 for the conjugates contained in the composition. Thus, such tri-PEGylated compositions are homogeneous in terms of the degree of PEGylation, in particular the number of attached branched PEG moieties, but are heterogeneous in terms of the position of PEG attachment on IL-2, and in this case represent positional isomers of PEG attachment.
[0056] The composition may also include a single conjugate in which n is equal to 1, for example, a mono-PEGylated conjugate in which one branched polyethylene glycol moiety is attached at the same relative position for substantially all IL-2 conjugates in the composition. Alternatively, the mono-PEGylated conjugate may include a mixture of mono-PEGylated conjugates, for example, a mixture of mono-PEGylated conjugates in which the attachment site of the branched polyethylene glycol moiety is present at different sites on IL-2 for the conjugates contained in the composition. Thus, such mono-PEGylated compositions are homogeneous in terms of the degree of PEGylation, in particular the number of attached branched PEG moieties, but are heterogeneous in terms of the position of PEG attachment on IL-2, and in this case represent positional isomers of PEG attachment.
[0057] Certain positions of PEG attachment on the IL-2 molecule are more prevalent in the compositions described herein. For example, lysine K7 or K8 or K31 or K75 are often sites of PEGylation. 20kD-IL-2 compositions and related compositions may comprise conjugates wherein lysine K7 or K8 or K31 or K75 is the site of PEGylation. 20kD -IL-2 compositions and related compositions may comprise mono-PEGylated conjugates wherein lysine K7 or K8 or K31 or K75 is the site of PEGylation. 20kD -IL-2 compositions and related compositions may include mono-PEGylated conjugates in which lysine K7 is the site of PEGylation. 20kD -IL-2 compositions and related compositions may comprise a mono-PEGylated conjugate in which lysine K31 is the site of PEGylation.
[0058] In some embodiments, the composition contains no more than about 20 mol%, and preferably no more than about 15 mol% of the conjugates covered by formula (I) when considered together, wherein n' is an integer selected from 1, 4, 5, or an integer greater than 5, wherein the molar percentage is based on the total PEG-IL-2 conjugate. In some embodiments, the composition contains no more than about 10 mol% of the conjugates covered by formula (I) when considered together, wherein n' is an integer selected from 1, 4, 5, or an integer greater than 5, wherein the molar percentage is based on the total PEG-IL-2 conjugate. In some additional embodiments, the composition contains no more than about 10 mol% of monomers, and preferably no more than about 7 mol% of monomers, or no more than about 5 mol% of monomers (i.e., according to structure (I), wherein n is equal to 1). In some further embodiments, the composition contains no more than about 10 mol% of tetramers, and preferably no more than about 7 mol% of tetramers, or no more than about 5 mol% of tetramers (i.e., according to structure (I), wherein n is equal to 4). In certain additional embodiments, the composition comprises no more than about 10 mol % of monomer and no more than about 10 mol % of tetramer. Alternatively, the composition comprises no more than about 7 mol % of monomer and no more than about 7 mol % of tetramer, or may comprise no more than about 5 mol % of monomer and no more than about 5 mol % of tetramer.
[0059] In some embodiments, with respect to the PEGylated IL-2 in the composition, the composition will generally meet one or more of the following characteristics: at least about 80% of the conjugates in the composition will comprise a mixture of di-PEGylated and tri-PEGylated conjugates, some having 2 branched polymers having the structure shown in formula (I) above attached to the IL-2 portion, and some having 3 branched polymers having the structure shown in formula (I) above attached to the IL-2 portion; at least about 85% of the conjugates in the composition will comprise di-PEGylated and tri-PEGylated conjugates; The invention relates to a mixture of di-PEGylated and tri-PEGylated conjugates, some having 2 branched polymers having the structure shown in formula (I) above attached to the IL-2 portion and some having 3 branched polymers having the structure shown in formula (I) above attached to the IL-2 portion; at least about 90% of the conjugates in the composition will comprise a mixture of di-PEGylated and tri-PEGylated conjugates, some having 2 branched polymers having the structure shown in formula (I) above attached to the IL-2 portion and some having 3 branched polymers having the structure shown in formula (I) above attached to the IL-2 portion. 2 moieties; and at least about 95% of the conjugates in the composition will comprise a mixture of di-PEGylated and tri-PEGylated conjugates, some having 2 branched polymers having the structure shown in formula (I) above attached to the IL-2 moiety and some having 3 branched polymers having the structure shown in formula (I) above attached to the IL-2 moiety; no more than about 20% of the conjugates in the composition will have 1 or 4 or more branched polymers having the structure shown in formula (I) above attached to the IL-2 moiety; no more than about 15% of the conjugates in the composition will have 1 or 4 or more branched polymers having the structure shown in formula (I) above attached to the IL-2 portion; no more than about 10% of the conjugates in the composition will have 1, 4 or more branched polymers having the structure shown in formula (I) above attached to the IL-2 portion; no more than about 7% of the conjugates in the composition will have 1 or 4 or more branched polymers having the structure shown in formula (I) above attached to the IL-2 portion.
[0060] In some embodiments, the composition contains no more than about 20 mol%, and preferably no more than about 15 mol% of the compound covered by formula (I) when considered together, wherein n' is an integer selected from 1,4,5, or an integer greater than 5, wherein the molar percentage is based on the total PEG-IL-2 conjugate. In some embodiments, the composition contains no more than about 10 mol% of the conjugate covered by formula (I) when considered together, wherein n' is an integer selected from 1,4,5, or an integer greater than 5, wherein the molar percentage is based on the total PEG-IL-2 conjugate. In some additional embodiments, the composition contains no more than about 10 mol% of monomers, and preferably no more than about 7 mol% of monomers, or no more than about 5 mol% of monomers (i.e., according to structure (I), wherein n is equal to 1). In some further embodiments, the composition contains no more than about 10 mol% of tetramers, and preferably no more than about 7 mol% of tetramers, or no more than about 5 mol% of tetramers (i.e., according to structure (I), wherein n is equal to 4). In certain additional embodiments, the composition comprises no more than about 10 mol % of monomer and no more than about 10 mol % of tetramer. Alternatively, the composition comprises no more than about 7 mol % of monomer and no more than about 7 mol % of tetramer, or may comprise no more than about 5 mol % of monomer and no more than about 5 mol % of tetramer.
[0061] In some further embodiments, the composition comprises approximately equimolar amounts of
[0062]
[0063] .
[0064] For example, illustrative compositions may include any one or more of the following approximate ratios of di-PEGylated species to tri-PEGylated species: 1.4:1; 1.3:1; 1.2:1; 1.1:1; 1:1; 1:1.1; 1:1.2; 1:1.3; or 1:1.4. Such compositions have an average number of PEG moieties per IL-2 selected from, for example, 2; 2.1; 2.2; 2.3; 2.4; 2.5; 2.6; 2.6; 2.7; 2.8; 2.9; and 3. In certain embodiments, the average number of PEG moieties per IL-2 is about 2.5.
[0065] For example, in some embodiments, the composition comprises no more than about 20 mole % (mol %) of an IL-2 conjugate encompassed by the formula:
[0066]
[0067] wherein n' is selected from 1, 4, 5, or an integer greater than 5.
[0068] In still some additional embodiments, the composition comprises no more than about 15 mole % (mol %) of an IL-2 conjugate encompassed by the formula:
[0069]
[0070] And wherein n' is selected from 1, 4, 5, or an integer greater than 5.
[0071] In still some further embodiments, the composition comprises no more than about 10 mole % (mol %) of an IL-2 conjugate encompassed by the formula:
[0072]
[0073] And wherein n' is selected from 1, 4, 5, or an integer greater than 5.
[0074] In some additional embodiments of the foregoing, the composition comprises no more than about 10 mol % of the IL-2 conjugate where n' is equal to 1. In still other embodiments, the composition comprises no more than about 7 mol % of the IL-2 conjugate where n' is equal to 1.
[0075] In still further embodiments, the composition comprises no more than about 5 mol % of IL-2 conjugates where n' is equal to 1. In still other alternative embodiments, the composition comprises less than about 5 mol % of IL-2 conjugates where n' is equal to 1.
[0076] In some further embodiments related to any one or more of the foregoing, the composition comprises no more than about 10 mol % of IL-2 conjugates with n' equal to 4. Alternatively, in some other embodiments, the composition comprises no more than about 7 mol % of IL-2 conjugates with n' equal to 4. In still further embodiments, the composition comprises no more than about 5 mol % of IL-2 conjugates with n' equal to 4.
[0077] Also provided herein are compositions comprising approximately equimolar amounts of
[0078]
[0079] .
[0080] In yet additional embodiments, provided herein are compositions comprising an IL-2 conjugate of the formula,
[0081]
[0082]
[0083] wherein the molar ratio of the diPEG / triPEG conjugate is selected from 1.4:1; 1.3:1; 1.2:1; 1.1:1; 1:1; 1:1.1; 1:1.2; 1:1.3; and 1:1.4.
[0084] In some further embodiments, the average number of branched polyethylene glycol moieties (having the structure shown above) per IL-2 residue of the composition is selected from 2; 2.1; 2.2; 2.3; 2.4; 2.5; 2.6; 2.6; 2.7; 2.8; 2.9; and 3. In a specific embodiment, the average number of branched polyethylene glycol moieties (having the structure shown above) per IL-2 moiety is about 2.5. In some embodiments related to one or more of the foregoing, n has a value ranging from 5 to 2000. In some other embodiments, n has a value ranging from 10 to 1000. In some additional embodiments, n has a value ranging from 10 to 750. In some embodiments, n has a value ranging from 10 to 500, or 20 to 250.
[0085] In the embodiments provided herein, the value of n can vary independently at each occurrence. In one or more embodiments described herein, the value of n in each polyethylene glycol arm of a branched polymer is substantially the same. In some further embodiments, the value of n in each polymer arm constituting a branched polymer ranges from about 170 to 285. In some further embodiments, the value of n in each polymer arm constituting a branched polymer ranges from about 204 to about 250. In one or more specific embodiments, the value of n in each polymer arm constituting a branched polymer is about 226.
[0086] In one or more embodiments related to any one or more of the aspects or embodiments provided herein, the nominal average molecular weight of each branched polyethylene glycol portion is in the range of about 250 daltons to about 90,000 daltons. In some other embodiments, the nominal average molecular weight of each branched polyethylene glycol portion is in the range of about 1000 daltons to about 60,000 daltons. In further embodiments, the nominal average molecular weight of each branched polyethylene glycol portion is in the range of about 5,000 daltons to about 60,000 daltons. In some other embodiments, the nominal average molecular weight of each branched polyethylene glycol portion is in the range of about 10,000 daltons to about 55,000 daltons.
[0087] In still some additional embodiments, the nominal average molecular weight of each branched polyethylene glycol portion is in the range of about 15,000 daltons to about 25,000 daltons. In still one or more further embodiments, the nominal average molecular weight of each branched polyethylene glycol portion is in the range of about 18,000 daltons to about 22,000 daltons. In still some further embodiments, the nominal average molecular weight of each branched polyethylene glycol portion is about 20,000 daltons.
[0088] Additional exemplary compositions include compositions according to the above formula, wherein the overall polymer portion of the molecule has a nominal average molecular weight in the range of about 250 Daltons to about 90,000 Daltons. Additional suitable ranges for the polymer portion of the molecule include a nominal average molecular weight selected from the range of about 1,000 Daltons to about 60,000 Daltons, about 5,000 Daltons to about 60,000 Daltons, about 10,000 Daltons to about 55,000 Daltons, about 15,000 Daltons to about 50,000 Daltons, and about 20,000 Daltons to about 50,000 Daltons.
[0089] Additional illustrative weight average molecular weights of the polyethylene glycol polymer portion include about 200 Daltons, about 300 Daltons, about 400 Daltons, about 500 Daltons, about 600 Daltons, about 700 Daltons, about 750 Daltons, about 800 Daltons, about 900 Daltons, about 1,000 Daltons, about 1,500 Daltons, about 2,000 Daltons, about 2,200 Daltons, about 2,500 Daltons, about 3,000 Daltons, about 4,000 Daltons, about 4,400 Daltons, about 4,500 Daltons, about 5,000 Daltons, about 5,500 Daltons, about 6,000 Daltons, about 7,000 Daltons, about 7,500 Daltons, and about 8 In some preferred embodiments, the weight average molecular weight of the branched polyethylene glycol polymer is about 20,000 daltons. In some specific embodiments wherein each branched PEG moiety has a nominal molecular weight of about 20,000 Daltons, when the overall composition is characterized, the resulting molecular weight range of the composition is about 55 to 75 kDa.
[0090] Further embodiments of the selective Treg stimulator compositions provided herein include pharmaceutically acceptable salts thereof. As described above, the IL-2 conjugate composition may be in the form of a pharmaceutically acceptable salt. Typically, such salts are formed by reacting with a pharmaceutically acceptable acid or acid equivalent. In this regard, the term "pharmaceutically acceptable salt" generally refers to relatively nontoxic inorganic and organic acid addition salts. These salts can be prepared in situ during the administration of a vehicle or a dosage form manufacturing process, or by reacting a long-acting interleukin-2 composition as described herein with a suitable organic or inorganic acid and separating the salts thus formed. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, phosphate, nitrate, acetate, valerate, oleate, palmitate, stearate, laurate, benzoate, lactate, phosphate, toluenesulfonate, citrate, maleate, fumarate, succinate, tartrate, naphthoate, oxoate, mesylate, glucoheptonate, lactobionate, and laurylsulfonate, etc. (See, e.g., Berge et al. (1977) "Pharmaceutical Salts" , J. Pharm. Sci . 66:1-19). Thus, the salts described can be derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, aminosulfonic acid, phosphoric acid, nitric acid, etc.; or prepared from organic acids such as acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, palmitic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isothionic acid, etc. As used herein, the term "composition" or "compositions" includes the RUR described herein. 20kD -IL-2 embodiments and related compositions comprising any and / or all pharmaceutically acceptable salts of PEGylated IL-2 conjugates. This description applies whether the term "or a pharmaceutically acceptable salt thereof" is added to the description of the composition.
[0091] Method of use implementation plan
[0092] Compared to unmodified IL-2, the selective Treg stimulatory composition (including RUR described herein) 20kD -IL-2 embodiments and related compositions) address potential pathologies associated with autoreactive immunity, as well as target-specific mechanisms that produce beneficial T cell functions, and provide significant improvements over the administration of unmodified IL-2. In order to address the defects in existing autoimmune disease therapies, the compositions of the present invention provide sustained exposure after administration and have a unique pharmacological profile. The compositions of the present invention selectively amplify and activate endogenous Tregs in vivo, wherein the amplification of conventional T cells and / or natural killer cells is limited, and thus provide an excellent method for treating autoimmune diseases.
[0093] More specifically, selective Treg stimulatory compositions (including RUR provided herein) having a specific and predominant number of branched polyethylene glycol moieties stably covalently linked to IL-2 via their amino groups have been discovered. 20kD -IL-2 embodiments and related compositions) are particularly effective when administered at low doses. The compositions of the invention effectively bind and activate IL-2 receptors to preferentially increase the cell population and immunosuppressive function of regulatory T cells (Tregs) while having minimal stimulation of T effector cells (Teffs). Continuous exposure to the compositions of the invention (generally referred to herein as RURs) in rodents, non-human primates studies, and human clinical studies 20kD-IL-2 and related compositions, or otherwise referred to as RUR-IL-2 compositions) effectively provide the magnitude, duration, and specificity of Treg vs. Teff responses that are not achievable with equivalent doses of unmodified IL-2.
[0094] Administration of a single low ascending subcutaneous dose of a selective Treg stimulator composition RUR to a human 20kD -IL-2 (as described in the supporting examples) did not cause dose-limiting toxicity, serious adverse events or clinically significant abnormalities. Preliminary pharmacokinetic analysis showed that in most subjects, the composition reached maximum concentrations around 4-6 days after administration, with little change in concentration for up to approximately 2 weeks after administration, after which the concentration declined with a half-life of approximately 8-9 days. Preliminary pharmacodynamic evaluation revealed that administration of the selective long-acting IL-2 receptor agonist Treg stimulator composition resulted in a decrease in circulating CD4+FoxP3+CD25 亮 Dose-dependent increase in Tregs, i.e., circulating CD4+FoxP3+CD25 亮 The absolute number of Tregs continued to increase, with levels not returning to baseline until approximately 20 to 25 days after administration. 亮 The number of Tregs increased several-fold on average (with the magnitude depending on the dose). The overall CD4+ FoxP3+ CD25+ Treg population also increased, although the magnitude of the change was less than that observed for CD4+ FoxP3+ CD25 bright Tregs. For the lowest dose, there was no change in the number of Tregs in treated subjects compared to placebo subjects. A major effect was seen on Tregs, as the effect of RUR on Tregs was not significantly different at any dose. 20kD -IL-2 compositions did not observe changes in the percentage or number of T cell populations (CD4+, CD8+). Thus, the compositions and methods of the present invention are surprisingly effective in increasing the suppressive capacity of Tregs in in vivo / ex vivo bioassays (even when compared to alternative chemically modified IL-2 compounds) and also in human studies (as will be described), together with other features in the following sections.
[0095] The selective Treg stimulatory compositions provided herein (including RUR 20kD -IL-2 embodiments and related compositions) can be used to treat, among other things, autoimmune diseases and disorders. 20kDExemplary autoimmune diseases treated with -IL-2 compositions include systemic conditions such as systemic lupus erythematosus (SLE), ulcerative colitis, Crohn's disease, rheumatoid arthritis, atopic dermatitis, systemic sclerosis, ankylosing spondylitis, graft-versus-host disease, and polymyositis; or organ-specific autoimmune diseases including type 1 diabetes, Addison's disease, Hashimoto's thyroiditis, Graves' disease, Sjogren's syndrome, vitiligo, pernicious anemia, glomerulonephritis, myasthenia gravis, Goodpasture's syndrome, autoimmune hemolytic anemia, idiopathic thrombocytopenic purpura, peanut allergy, and pulmonary fibrosis.
[0096] In some embodiments, the condition treated is systemic lupus erythematosus (SLE). Systemic lupus erythematosus (SLE) is an autoimmune inflammatory disease that mainly affects middle-aged women. The characteristics of SLE include, for example, skin rashes, joint pain, recurrent pleurisy and kidney disease. The progressive homeostasis imbalance of Treg relative to Tcon is shared by many autoimmune diseases (including SLE). In general, the therapeutic hypothesis of associating Treg homeostasis with the pathology of SLE, the activity of low-dose IL-2 in SLE patients and RUR described herein 20kD -IL-2 and related compositions have superior Treg induction properties relative to IL-2, such as RUR-IL-2 or RUR 20kD -IL-2 and its related compositions provide ample support for the use in treating SLE and other autoimmune diseases and conditions. In one or more further embodiments, provided herein is a method for treating SLE by administering RUR-IL-2 or RUR as described herein. 20kD -IL-2-related compositions for treating a condition, wherein the condition is selected from, for example, allergy, GVHD, Crohn's disease, ulcerative colitis, rheumatoid arthritis, type 1 diabetes, multiple sclerosis and psoriasis.
[0097] In still further embodiments, when administered to a subject at a therapeutically effective dose, the RUR-IL-2 or RUR 20kD -IL-2 related compositions are effective in preferentially expanding and activating regulatory T cells over conventional T cells and natural killer cells.
[0098] In another aspect, provided herein is a method of administering to a subject a therapeutically effective dose of RUR-IL-2 or RUR as described herein. 20kD -IL-2 related compositions to increase the ratio of regulatory T cells to effector T cells in the subject.
[0099] In some embodiments related to the foregoing methods, the regulatory T cells are selected from Foxp3+ and CD25+ cells. In one or more embodiments related to the previous embodiments or methods, the effector T cells are selected from CD4+ and CD8+ cells.
[0100] In some further embodiments related to the above methods or related embodiments, the fold increase in regulatory T cells reaches a value of at least about 2, or at least about 4, or even at least about 6 when compared to baseline when assessed in an in vivo mouse model.
[0101] In some embodiments of the method, after administration, the increase in the number of regulatory T cells is maintained above the baseline level for at least 3 days. In some additional embodiments, after administration, the increase in the number of regulatory T cells is maintained above the baseline level for at least 5 days. Preferably, the increase in the number of regulatory T cells is maintained above the baseline level for at least 7 days.
[0102] In yet a further aspect, provided herein is a method of treating a subject having an autoimmune disease, comprising administering to the subject a therapeutically effective amount of a selective Treg stimulatory composition comprising RUR-IL-2 or RUR as described above or elsewhere herein. 20kD -IL-2 related composition embodiments.
[0103] In yet a further aspect, provided herein is a method of treating a subject having an autoimmune disease, comprising administering to the subject a therapeutically effective amount of a composition selected from the group consisting of: RUR 20kD -IL-2 Formula A, RUR 20kD -IL-2 Formula B, RUR 20kD -IL-2 Formula C, RUR 20kD -IL-2 Formula D and RUR 20kD -IL-2 Formula E.
[0104] In yet a further aspect, provided herein is a method of treating a subject having an autoimmune disease, comprising administering to the subject a therapeutically effective amount of a composition selected from the group consisting of: RUR 20kD -IL-2 Formula A, RUR 20kD -IL-2 Formula B and RUR 20kD -IL-2 Formula C.
[0105] In yet a further aspect, provided herein is a method of treating a subject having an autoimmune disease comprising administering to the subject a therapeutically effective amount of RUR 20kD - Composition of IL-2 Formula A.
[0106] In yet a further aspect, provided herein is a method of treating a subject having an autoimmune disease comprising administering to the subject a therapeutically effective amount of RUR 20kD - Composition of IL-2 formulation B.
[0107] In yet a further aspect, provided herein is a method of treating a subject having an autoimmune disease comprising administering to the subject a therapeutically effective amount of RUR 20kD - Composition of IL-2 formulation C.
[0108] In yet a further aspect, provided herein is the use of a composition selected from the group consisting of: RUR 20kD -IL-2 Formula A, RUR 20kD -IL-2 Formula B, RUR 20kD -IL-2 Formula C, RUR 20kD -IL-2 Formula D and RUR 20kD -IL-2 Formula E.
[0109] In yet a further aspect, provided herein is a RUR 20kD - Use of the composition of IL-2 Formula A in therapy.
[0110] In yet a further aspect, provided herein is a RUR 20kD - Use of the composition of IL-2 formulation B in therapy.
[0111] In yet a further aspect, provided herein is a RUR 20kD - Use of the composition of IL-2 formulation C in therapy.
[0112] In yet a further aspect, provided herein is a RUR 20kD - Use of the composition of IL-2 formulation D in therapy.
[0113] In yet a further aspect, provided herein is a RUR 20kD - Use of the composition of IL-2 Formula E in therapy.
[0114] In yet a further aspect, provided herein is the use of a selective Treg stimulator composition selected from the group consisting of: RUR 20kD -IL-2 Formula A, RUR 20kD -IL-2 Formula B, RUR 20kD -IL-2 Formula C, RUR 20kD -IL-2 Formula D and RUR 20kD -IL-2 Formula E.
[0115] In a more specific embodiment, the treatment of systemic lupus erythematosus (SLE) comprises subcutaneously administering a therapeutically effective amount of RUR-IL-2 or RUR 20kD - Preparation of IL-2 related compositions. See, for example, the results described in Example 8, which illustrate that RUR 20kD - The effect of IL-2 composition-induced Treg on the physiological immune response and control of disease progression in a representative animal model of SLE. As described therein, RUR 20kD - The IL-2 composition effectively suppressed biomarkers of kidney damage, one of the characteristics of patients with SLE, to levels nearly identical to those observed in normal mice.
[0116] In embodiments relating to methods of treatment as described herein, such embodiments are also further embodiments for use in the treatment or alternatively for the preparation of a medicine for use in the treatment. The disclosure further provides a composition according to any one of the embodiments of the compositions as described herein (including preparations thereof), which is used in therapy. The disclosure further provides a composition according to any one of the embodiments of the compositions as described herein (including preparations thereof), which is used to treat autoimmune diseases.
[0117] In one aspect, the present disclosure provides a composition comprising a PEGylated IL-2 conjugate having the structure:
[0118]
[0119]
[0120] in:
[0121] IL-2 is interleukin-2;
[0122] n is independently at each occurrence an integer from about 3 to about 4000;
[0123] It is used in therapy. In a specific embodiment of the composition for use in therapy, IL-2 is aldesleukin. In a specific embodiment of the composition for use in therapy, the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons. In a further specific embodiment of the composition for use in therapy, the PEGylated IL-2 conjugate of the composition has a PEG moiety attached at lysine 31. In a specific embodiment of the composition for use in therapy, therapy is used in autoimmune diseases.
[0124] the term
[0125] In describing and claiming certain features of the present disclosure, the following terminology will be used in accordance with the definitions in the following description, unless otherwise noted.
[0126] The term "selectivity" as used and described herein refers to an in vivo immune response, which embodies the characteristics of induced immune cells or immune signal responses in some aspects, but not in other aspects. Specifically, "selectivity" for Treg induction and / or activation refers to an immune response, which presents an increase in Treg cell number (by flow cytometry, CD25 is high and overall), and / or Treg activation state increases, as shown by one or more activation markers, such as ICOS or Ki67 or Stat5, and / or activation refers to downstream induced immunosuppressive response and / or induced immune tolerance response, and lacks some other immune responses. In this context, "selective Treg induction" refers to the immune response of Treg as described, while lacking significant and / or clinically important effector T cells and related immune activation responses. Important and / or clinically important effector T cells and related immune activation responses include, for example, CD4 positive T effector cells and / or CD8 positive T effector cell proliferation, and / or activation markers, such as ICOS or Ki67, or other well-known effector immune responses. Other effector immune response signals may include certain pro-inflammatory cytokines, such as those known as the "cytokine syndrome," and / or cytokines such as IL-5, INF γ , IL-6, IFN α , IL-17, IL-22, IL-19. Selective Treg stimulation can also be reflected in the average Treg:Tcon ratio. Preferably, the average Treg:Tcon ratio achieved in response to the RUR-IL-2 or RUR20kD-IL-2-related compositions described herein is at least 5 times, and preferably 7 times, and more preferably 10 times or more.
[0127] As used herein, the term "degree of PEGylation" refers to the number of stable PEG substituents covalently attached to one or more amino groups of an individual aldesleukin polypeptide.
[0128] The term "about" as used herein means within a reasonable vicinity of a stated value, such as within plus or minus 10% of a stated value. Preferably, "about" or "approximately" as used herein means within plus or minus 5% of a given amount.
[0129] As used herein, the term "n' is 2 and 3" refers to a mixture of IL-2 conjugates, wherein the mixture comprises di-PEGylated and tri-PEGylated conjugates as described herein.
[0130] The term "regulatory T cells" or "Tregs" refers to T cells, such as CD4+FoxP3+CD25 亮Phenotype. (See, e.g., Jeffrey A. Bluestone and Qizhi Tang, Treg cells—the next frontier of cell therapy, Science, 12 October 2018 • Vol. 362 Issue 6411, p154-155.)
[0131] The term "Tcon" or "conventional T cell" refers to a T lymphocyte that expresses the αβ T cell receptor (TCR) and the co-receptors CD4 or CD8 and performs well-established adaptive immune effector functions, such as T helper cell function and cytotoxic T cell effector function. For example, Tcon can refer to CD4 + CD25 - Naive conventional T cells. "Effector T cells (Teff)" refers to CD4+ and CD8+ cell effector phenotypes, such as helper T cells, cytotoxic T cells and others, as known to the skilled artisan. "NK cells", also known as "natural killer cells", "K cells" or "killer cells", are a type of lymphocyte (white blood cell) and a component of the innate immune system. NK cells play a major role in host rejection of tumors and virus-infected cells.
[0132] "IL-2 intermediate" refers to an IL-2 polypeptide, particularly aldesleukin. 20kD "-IL-2" refers to an IL-2 PEG conjugate, wherein the IL-2 portion is aldesleukin as described herein, and the PEG portion is as described herein. 20kD -IL-2 compositions may also be referred to in a general manner by the chemical name (1,3-bis(methoxypoly(ethylene glycol) 10kD As used herein, aldesleukin refers to 125-L-serine-2-133 interleukin-2, a recombinant non-glycosylated interleukin-2 expressed in Escherichia coli. The amino acid sequence of aldesleukin is shown in Figure 2 Aldesleukins expressed in other host systems known to the skilled artisan are also within the meaning of the term as used herein.
[0133] As used herein, the term "IL-2" refers to a part with human IL-2 activity. The term "IL-2 part" refers to the IL-2 part before being attached to the branched polyethylene glycol part and the IL-2 part after covalent attachment. It should be understood that when the original IL-2 part is attached to a polyethylene glycol polymer, such as a branched polyethylene glycol polymer provided herein, the IL-2 part is slightly changed due to the presence of one or more covalent bonds associated with the connection to the polyethylene glycol part. This slightly changed form of the IL-2 part attached to another molecule is referred to as the "residue" of the IL-2 part in this article. In the context of the residue of IL-2, the term 'residue' means that the IL-2 molecule is covalently attached to a polymer, such as a polyethylene glycol, at one or more covalent attachment sites. The part retained after, as shown in the formula herein. Typically, the site of attachment will be one of the 11 amine groups of the lysine in IL-2.
[0134] It should be understood that when unmodified IL-2 is attached to a polymer, such as polyethylene glycol, the IL-2 is slightly altered due to the presence of one or more covalent bonds associated with the connection to the polymer. This slightly altered form of IL-2 attached to another molecule, such as a branched PEG moiety, may be referred to as a "residue" of IL-2 in some cases, or may be simply referred to as "IL-2", etc., where it is understood that the IL-2 contained in this polymer conjugate is slightly altered due to the presence of one or more covalent bonds (each covalent bond connecting the branched PEG moiety to IL-2). The term "higher PEGylated IL-2 conjugate" refers to a tetraPEG conjugate or a pentaPEG conjugate or a conjugate of up to 11 PEG moieties. Preferably, a "higher PEGylated IL-2 conjugate" refers to a tetraPEG conjugate or a pentaPEG conjugate.
[0135] For example, a protein having an amino acid sequence corresponding to any one of SEQ ID NOs: 1 to 4 described in International Patent Publication No. WO 2012 / 065086 is an exemplary IL-2 protein, as is any protein or polypeptide substantially homologous thereto. The term substantially homologous means that a specific subject sequence, such as a mutant sequence, differs from a reference sequence by one or more substitutions, deletions or additions, the net effect of which does not result in an adverse functional difference between the reference sequence and the subject sequence. For the purposes of this article, sequences having greater than 95% homology, equivalent biological activity (although not necessarily biological activity of equivalent strength) and equivalent expression characteristics are considered to be substantially homologous. For the purpose of determining homology, truncation of mature sequences should be ignored. As used herein, the term "IL-2" includes such proteins that are intentionally modified, for example, by site-directed mutagenesis or accidentally by mutation. These terms also include analogs with 1 to 6 additional glycosylation sites, analogs with at least one additional amino acid at the carboxyl terminus of the protein (wherein the additional amino acid includes at least one glycosylation site), and analogs with an amino acid sequence including at least one glycosylation site. The term includes both natural and recombinantly produced parts. In addition, IL-2 can be derived from human sources, animal sources, and plant sources. An exemplary IL-2 is human recombinant IL-2 called aldesleukin (see Figure 2 ). References to the long-acting IL-2R agonists as described herein are intended to encompass pharmaceutically acceptable salt forms thereof.
[0136] In one aspect, RUR-IL-2 or RUR described herein 20kD -IL-2 related compositions are long-acting agents. 20kD -Long-acting of an IL-2-related composition means that such composition has a circulating half-life in plasma that is extended relative to the circulating half-life of an unmodified identical IL-2R agonist (e.g., aldesleukin or other suitable IL-2 sequence). For example, the comparator agonist is not modified by covalent attachment to one or more water-soluble polymer moieties, such as polyethylene glycol moieties, and is compared to a protein-equivalent dose of the IL-2R agonist administered to the same subject and evaluated by the same pharmacokinetic analysis.
[0137] As used herein, "PEG" or "polyethylene glycol" is intended to encompass any water-soluble poly(ethylene oxide). Unless otherwise indicated, a "PEG polymer" or polyethylene glycol is a polyethylene glycol in which substantially all (preferably all) monomer subunits are ethylene oxide subunits, however, the polymer may contain different end-capping moieties or functional groups, such as for conjugation. PEG polymers for use in the present disclosure will comprise one of the following two structures: "-(CH 2 CH2 O) n -"or"-(CH 2 CH 2 O) n- 1 CH 2 CH 2 -", depending on whether the terminal oxygen has been replaced, for example, during a synthetic transformation. As described above, for PEG polymers, the variable (n) ranges from about 3 to 4000, and the terminal groups and structure of the overall PEG can vary. Preferably, PEG has a specific meaning as described in detail herein.
[0138] "Branched," with respect to the geometry or overall structure of a polymer, refers to a polymer having two or more polymer "arms" or "chains" extending from a branching point or central structural feature. As an example, the illustrative PEG reagent, mPEG2-butyric acid, N-hydroxysuccinimide ester (1,3-bis(methoxypoly(ethylene glycol)carbamoyl)-2-propoxy)-4-succinimidylbutyrate) is a branched polyethylene glycol polymer composed of two linear PEG chains, each covalently attached to the 1- and 3-carbons of a central propyl group, respectively, via a carbamate linkage (~NHC(O)O~), from which the succinimidyloxybutyrate extends.
[0139] The molecular weight in the context of water-soluble polymers, such as PEG, can be expressed as number average (nominal average) molecular weight or weight average molecular weight. Unless otherwise specified, all references to molecular weight herein refer to nominal average molecular weight. Both molecular weight determinations (number average and weight average) can be measured using gel permeation chromatography, gel filtration chromatography or other liquid chromatography techniques. Other methods for measuring molecular weight values can also be used, such as using end group analysis or measuring colligative properties (e.g., freezing point depression, boiling point elevation or osmotic pressure) to determine the number average molecular weight or using light scattering techniques, ultracentrifugation or viscometry to determine the weight average molecular weight. Gel filtration chromatography is often used to determine the average molecular weight of branched polymers. PEG polymers are usually polydisperse (i.e., the number average molecular weight and weight average molecular weight of the polymer are not equal), preferably less than about 1.2, more preferably less than about 1.15, still more preferably less than about 1.10, still more preferably less than about 1.05 and most preferably less than about 1.03 low polydispersity values.
[0140] A "stable" linkage or bond refers to a chemical bond that is substantially stable in water, that is, does not undergo hydrolysis to any appreciable extent under physiological conditions over an extended period of time. Examples of hydrolytically stable linkages generally include, but are not limited to, the following: carbon-carbon bonds (e.g., in aliphatic chains), ethers, amides, amines, and the like. Typically, a stable linkage is one that exhibits a hydrolysis rate of less than about 1-2% per day under physiological conditions. The hydrolysis rates of representative chemical bonds can be found in most standard chemistry textbooks.
[0141] As used in this specification, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise.
[0142] "Substantially" or "essentially" means approximately the entirety or whole, for example, 95% or more of a given amount, unless indicated to the contrary.
[0143] Preparation and Examples
[0144] It should be understood that the preparation and examples are described by way of illustration and not limitation, and that various modifications may be made by one of ordinary skill in the art. 20kD -IL-2 embodiments and related compositions). Reagents and starting materials are readily available or can be easily synthesized by a person of ordinary skill in the art. Suitable conditions for the steps of these methods are well known, and suitable substitutions of buffers and reagents are within the skill of the art. In addition, the skilled person will appreciate that in some cases, the steps and sequence for producing the compositions may be modified and are well understood by skilled biochemists. Likewise, it should be appreciated that the preparations may be separated and / or purified by various well-known techniques as needed or desired.
[0145] Preparation of IL-2 intermediates:
[0146] The IL-2 portion can be derived from non-recombinant and / or recombinant methods, and the present disclosure is not limited in this regard. The IL-2 portion can be derived from human sources, animal sources, and plant sources. For example, it is possible to isolate IL-2 from a biological system and obtain IL-2 from a culture medium in other ways. See, for example, U.S. Pat. No. 4,401,756 and Pauly et al. (1984) J. Immunol Methods The procedures described in 75(1):73-84.
[0147] Methods for producing and expressing recombinant polypeptides in vitro and in prokaryotic and eukaryotic host cells are well known to those of ordinary skill in the art. See, e.g., U.S. Pat. No. 5,614,185. The IL-2 portion can be expressed in bacteria [e.g., E. coli, see, e.g., Fischer et al. (1995) Biotechnol. Appl. BioIL-2m. 21(3):295-311], mammals [see, e.g., Kronman et al. (1992) Gene 121:295-304], yeast [e.g., Pichia pastoris, see, e.g., Morel et al. (1997) Biochem. J. 328(1):121-129] and plants [see, e.g., Mor et al. (2001) Biotechnol. Bioeng. 75(3):259-266] expression system. Although recombinant protein production methods can vary, recombinant methods generally involve constructing a nucleic acid encoding a desired polypeptide or fragment, cloning the nucleic acid into an expression vector, transforming a host cell (e.g., a plant, a bacterium, a yeast, a transgenic animal cell, or a mammalian cell (such as a Chinese hamster ovary cell or a baby hamster kidney cell), and expressing the nucleic acid to produce the desired polypeptide or fragment. Various protein purification methods can be used to purify the compositions of the present disclosure, and such methods are known in the art and are described, for example, in Scopes, Protein Purification: Principles and Practice , 3rd ed., Springer, NY (1994). To facilitate identification and purification of recombinant polypeptides, nucleic acid sequences encoding epitope tags or other affinity binding sequences may be inserted or appended in frame with the coding sequence, thereby generating a fusion protein consisting of the desired polypeptide and a polypeptide suitable for binding.
[0148] Depending on the system for expressing the protein with IL-2 activity, the IL-2 part can be unglycosylated or glycosylated, and any one can be used. That is, the IL-2 part can be unglycosylated, or the IL-2 part can be glycosylated, and in one or more preferred embodiments, the IL-2 part is unglycosylated. The IL-2 part can also be advantageously modified to include and / or replace one or more amino acid residues, such as, for example, lysine, cysteine and / or arginine, so as to provide easy attachment of the atoms in the side chain of the polymer and the amino acid. The example of the substitution of the IL-2 part is described in U.S. Patent number 5,206,344. In addition, the IL-2 part can be modified to include non-naturally occurring amino acid residues. The technology for adding amino acid residues and non-naturally occurring amino acid residues is well known to those of ordinary skill in the art.
[0149] In addition, the IL-2 portion can advantageously be modified to include the attachment of a functional group (except by adding an amino acid residue containing a functional group). For example, the IL-2 portion can be modified to include a sulfhydryl group. In addition, the IL-2 portion can be modified to include an N-terminal alpha carbon. In addition, the IL-2 portion can be modified to include one or more carbohydrate portions. In addition, the IL-2 portion can be modified to include an aldehyde group. In addition, the IL-2 portion can be modified to include a ketone group. In some embodiments of the present disclosure, it is preferred that the IL-2 portion is not modified to include one or more of a sulfhydryl group, an N-terminal alpha carbon, a carbohydrate, an aldehyde group, and a ketone group.
[0150] Exemplary IL-2 moieties are described in the literature, and, for example, in U.S. Patent Nos. 5,116,943, 5,153,310, 5,635,597, 7,101,965, and 7,567,215 and U.S. Patent Application Publication Nos. 2010 / 0036097 and 2004 / 0175337. Preferred IL-2 moieties have Figure 2 The amino acid sequence is provided in and represents the amino acid sequence of aldesleukin as used herein.
[0151] In some cases, the IL-2 portion will be in the form of a "monomer", in which a single expression of the corresponding peptide is organized into discrete units. In other cases, the IL-2 portion will be in the form of a "dimer" (e.g., a dimer of recombinant IL-2), in which two monomeric forms of the protein are associated with each other (e.g., via disulfide bonds). For example, in the context of a dimer of recombinant human IL-2, the dimer can be in the form of two monomers associated with each other via a disulfide bond, the disulfide bond being formed by the Cys125 residue of each monomer.
[0152] For any given peptide or protein portion or composition, it is possible to determine whether the portion has IL-2 activity. Various methods for determining in vitro IL-2 activity are described in the art and herein. One exemplary method is the CTTL-2 cell proliferation assay described herein. Exemplary methods are also described in Moreau et al. (1995) Mol. Immunol. 32:1047-1056). Briefly, in the non-specific binding assay, the proposed IL-2 fraction or composition was allowed to pre-incubate for 1 hour at 4°C in the presence of a cell line bearing a receptor for IL-2. 125 I-labeled IL-2 was incubated in the system at 4°C for 3 hours. Data are expressed as the % inhibitory capacity of the proposed IL-2 partial activity compared to wild-type IL-2. Other methods known in the art can also be used to evaluate IL-2 function, including electrometry, spectrophotometry, chromatography, and radiometry.
[0153] Selective Treg stimulatory agent composition (including RUR 20kD - Preparation of IL-2 embodiments and related compositions):
[0154] RUR 20kD -Exemplary selective Treg stimulatory compositions for IL-2 are typically prepared by reacting purified IL-2 with a molar excess of a PEG reagent (relative to the molar equivalent excess of IL-2), mPEG2 (20 kD) -butyric acid, N-hydroxysuccinimide ester (or any other suitable activated ester) (1,3-bis (methoxypoly (ethylene glycol) MW 10,000 carbamoyl) -2-propoxy) -4-succinimidyl butyrate in a bicine solution at a high pH of about 9. The reactants are typically mixed under mild conditions, such as from about 20°C to about 65°C, or from about 20°C to about 40°C, or at ambient or room temperature, for about 30 minutes to about 5 hours, or about 30 minutes to 4 hours, or about 30 minutes to 2 hours, or about 30 minutes to 1 hour. The reaction is quenched by acidifying to a low pH by adding a suitable acid, such as acetic acid.
[0155] The PEGylated rIL-2 reaction product is then purified by a suitable method, such as ion exchange chromatography. For example, when ion exchange chromatography is used, RUR 20kD The IL-2 composition is bound to the resin and then eluted with a suitable gradient, such as a sodium chloride gradient. The chromatography product pool is then concentrated and diafiltered into a suitable formulation buffer (e.g., sodium acetate buffer with sucrose) using, for example, tangential flow filtration (TFF).
[0156] If desired, the product pool can be further separated into positional isomers by using reverse phase chromatography using a reverse phase high performance liquid chromatography (RP-HPLC) using a suitable column (e.g., a C18 column or a C3 column, commercially available from companies such as Amersham Biosciences or Vydac) or by ion exchange chromatography using an ion exchange column (e.g., a Sepharose™ ion exchange column available from Amersham Biosciences). Either method can be used to separate polymer-active agent isomers having the same molecular weight (i.e., positional isoforms).
[0157] Selective Treg stimulatory agent composition (including RUR 20kD -IL-2 embodiments and related compositions) can be characterized by various analytical and bioassay techniques described herein and / or known to the skilled artisan, including analytical HPLC, SDS-Page, LCMS and bioassays such as CTLL-2 proliferation and in vivo Treg induction.
[0158] preparation:
[0159] In yet one or more embodiments, provided herein are selective Treg stimulator compositions comprising RUR 20kD -IL-2 embodiments and related compositions comprising an IL-2 conjugate composition as described herein, and a pharmaceutically acceptable excipient.
[0160] "Pharmaceutically acceptable excipient" or "pharmaceutically acceptable carrier" refers to a component that can be included in the composition described herein and does not cause significant adverse toxicological effects to the subject. The compositions of the present disclosure are preferably formulated as pharmaceutical compositions that are administered by any route that makes the composition bioavailable (such as parenteral administration, including intravenous, intramuscular or subcutaneous). Such pharmaceutical compositions and methods for preparing them are well known in the art (see, for example, Remington: The Science and Practice of Pharmacy (DB Troy, ed., 21st ed., Lippincott, Williams & Wilkins, 2006)). Optionally, the compositions provided herein may further comprise a pharmaceutically acceptable excipient, and exemplary excipients include, but are not limited to, those selected from the following: carbohydrates, inorganic salts, antimicrobial agents, antioxidants, surfactants, buffers, acids, bases, amino acids and combinations thereof. The amount of any individual excipient in the composition will vary depending on the activity of the excipient and the specific needs of the composition. Typically, the optimal amount of any individual excipient is determined experimentally, i.e., by preparing compositions containing different amounts of excipient (ranging from low to high), examining stability and other parameters, and then determining the range that achieves optimal performance without significant adverse effects. Carbohydrates, such as sugars, derivatized sugars, such as alditols, aldonic acids, esterified sugars, and / or sugar polymers can be present as excipients. Specific carbohydrate excipients include, for example: monosaccharides, such as fructose, maltose, galactose, glucose, D-mannose, sorbose, and the like; disaccharides, such as lactose, sucrose, trehalose, cellobiose, and the like; polysaccharides, such as raffinose, melezitose, maltodextrin, dextran, starch, and the like; and alditols, such as mannitol, xylitol, maltitol, lactitol, xylitol, sorbitol (glucitol), pyranosyl sorbitol, inositol, cyclodextrins, and the like. The excipient may also include an inorganic salt or buffer, such as citric acid, sodium chloride, potassium chloride, sodium sulfate, potassium nitrate, sodium dihydrogen phosphate, disodium hydrogen phosphate and combinations thereof. The composition may also include an antimicrobial for preventing or preventing microbial growth. Non-limiting examples of antimicrobials suitable for one or more embodiments of the present disclosure include benzalkonium chloride, benzethonium chloride, benzyl alcohol, cetylpyridinium chloride, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate, thimerosal and combinations thereof. Antioxidants may also be present in the composition. Antioxidants are used to prevent oxidation, thereby preventing the conjugate or other components of the preparation from deteriorating. Suitable antioxidants for one or more embodiments of the present disclosure include, for example, ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, hypophosphorous acid, monothioglycerol, propyl gallate, sodium bisulfite, sodium formaldehyde sulfoxylate, sodium metabisulfite and combinations thereof. Surfactants may be present as excipients.Exemplary surfactants include polysorbates such as "Tween 20" and "Tween 80", and pluronics such as F68 and F88 (both available from BASF, Mount Olive, New Jersey); sorbitan esters; lipids such as phospholipids such as lecithin and other phosphatidylcholines, phosphatidylethanolamines (although preferably not in liposomal form), fatty acids and fatty esters; steroids such as cholesterol; and chelating agents such as EDTA; zinc and other such suitable cations. Acids or bases may be present in the composition as excipients. Non-limiting examples of acids that may be used include those selected from the group consisting of hydrochloric acid, acetic acid, phosphoric acid, citric acid, malic acid, lactic acid, formic acid, trichloroacetic acid, nitric acid, perchloric acid, phosphoric acid, sulfuric acid, fumaric acid, and combinations thereof. Examples of suitable bases include, but are not limited to, bases selected from the group consisting of sodium hydroxide, sodium acetate, ammonium hydroxide, potassium hydroxide, ammonium acetate, potassium acetate, sodium phosphate, potassium phosphate, sodium citrate, sodium formate, sodium sulfate, potassium sulfate, potassium fumarate, and combinations thereof. One or more amino acids may be present in the compositions described herein as excipients. In this regard, exemplary amino acids include arginine, lysine, and glycine. Additional suitable pharmaceutically acceptable excipients include, for example, those described in Handbook of Pharmaceutical Excipients, 7th edition, Rowe, RC, ed., Pharmaceutical Press, 2012. Selective Treg stimulator compositions (including RUR provided herein. 20kD -IL-2 embodiments and related compositions) is 1.5 mg / ml protein equivalent, 10 mM sodium acetate, 110 mM sodium chloride, 2% sucrose (w / v), pH 5.0. RUR can be 20kD -IL-2 compositions are stored sterile and provided ready for use in sterile single-use polycarbonate bottles of appropriate volume with polypropylene caps with silicone liners.
[0161] Dosage:
[0162] Selective Treg stimulatory composition (including RUR provided herein) 20kD -IL-2 embodiments and related compositions) will vary depending on many factors, but will optimally be a therapeutically effective dose when the composition is stored in a unit dose container (e.g., a vial). In addition, the drug formulation can be contained in a syringe. Increasing amounts of a selective Treg stimulator composition (including RUR provided herein) can be administered by repeated administration. 20kD-IL-2 embodiments and related compositions) to experimentally determine a therapeutically effective dose to determine an amount that produces a clinically desirable endpoint as described herein (such as alleviation of autoimmune symptoms and / or immunosuppression, and / or induction of tolerance).
[0163] The amount of the preferred dosage is a low dose that effectively preferentially amplifies and activates regulatory T cells in a subject compared to conventional T cells and natural killer cells. The activation of regulatory T cells can be measured by many different methods. For example, in view of the overall effect of STAT5 in IL-2-dependent T cell processes, the detection of STAT5 increased in lymphocytes can be used as a key marker for Treg activation. Phenotypically, the activation of Treg can also be measured by flow cytometry by the intracellular expression of increased cell surface IL-2Rα (CD25) and / or increased protein forkhead box P3 (Foxp3) (the main regulator of Treg pedigree) and / or the expression of increased protein Ki67 associated with cell proliferation. Collectively, these markers are related to the function of Treg cells and are often dysregulated in such cells in autoimmune diseases. Herein, the preferred detection of Treg cell induction and activation is carried out by flow cytometry. The functionality of Treg can also be evaluated by an ex vivo inhibition assay, which measures its ability to suppress the proliferation of conventional T cells. The consequences of Treg mobilization and activation can also be directly measured in vivo using antigen-driven inflammation models.
[0164] RUR provided in this article 20kD Administration of the IL-2 embodiments and related compositions is typically performed via injection. Other modes of administration are also contemplated, such as pulmonary, nasal, buccal, rectal, sublingual, and transdermal. As used herein, the term "parenteral" includes subcutaneous, intravenous, intraarterial, intratumoral, intralymphatic, intraperitoneal, intracardiac, intrathecal, and intramuscular injections, as well as infusion injections. In a specific embodiment, the injection is subcutaneous. For example, the RUR provided herein may be injected 20kD -IL-2 embodiments and related compositions and compositions of diluents to achieve administration to patients. Regarding possible diluents, the diluent can be selected from, for example, antibacterial water for injection, 5% glucose in water, phosphate buffered saline, Ringer's solution, lactated Ringer's solution, saline, sterile water, deionized water and combinations thereof. One of ordinary skill in the art can determine by testing whether two given pharmacological components are compatible together in a given formulation. Exemplary compositions for administration to patients, such as subcutaneous formulations, include, for example, a therapeutically effective dose of RUR provided herein 20kD - IL-2 embodiments and related compositions, water, sodium acetate, sodium chloride and sucrose. The liquid composition will have a pH in the range of about 4.5-7.5; or about 4.5-6.
[0165] In certain embodiments, a selective Treg stimulatory composition (including a RUR provided herein) 20kD -IL-2 embodiments and related compositions) are in solid form. Preferred solid forms are those that are solid dry forms, such as those containing less than 5% by weight of water or preferably less than 2% by weight of water. The solid form is generally suitable for reconstitution in an aqueous diluent. Preferred solid formulations are stable for at least about 24 months when stored in a sealed container at a temperature of about 0-10°C.
[0166] The term "patient" or "subject" as used herein refers to a living organism suffering from or susceptible to a condition, such as an autoimmune disease, which can be prevented or treated by administering a composition as provided herein, and includes both humans and animals. Subjects include, but are not limited to, mammals (e.g., mice, monkeys, horses, cattle, pigs, dogs, cats, etc.), and are preferably humans. In certain embodiments, the patient, preferably a human, is further characterized by having a disease, disorder or condition, such as an autoimmune disease, which would benefit from the administration of the composition of the present disclosure.
[0167] As used herein, the term "treatment" or "treating" refers to the management and care of a patient with a condition for which the administration of the compositions of the present disclosure is indicated for the purpose of combating or alleviating the symptoms and complications of those conditions. Treatment includes administering the compositions of the present disclosure to a patient in need thereof to prevent the onset of symptoms or complications, alleviate the symptoms or complications, or eliminate the disease, condition or disorder. For example, an autoimmune disorder. Preferably, treatment includes administering the compositions of the present disclosure to a patient in need thereof to cause immunosuppression and / or tolerance. The patient to be treated is an animal, and preferably a human being. Administration as used herein includes situations in which the patient takes the composition and / or situations in which the patient is instructed to take the composition.
[0168] The phrases "pharmaceutically effective amount" and "pharmacologically effective amount" and "therapeutically effective amount" and "physiologically effective amount" are used interchangeably herein and refer to the RUR provided herein. 20kD -The amount of IL-2 and related compositions required to achieve the desired level of the substance in the bloodstream or target tissue. The exact amount will depend on many factors, such as, for example, the specific condition being treated, the intended patient population, individual patient considerations, the components and physical characteristics of the therapeutic composition to be administered, etc.
[0169] The pharmaceutical composition comprising the compound of the present disclosure can be administered parenterally to patients in need of such treatment. Parenteral administration can be carried out by means of a syringe, an optional pen-like syringe or a mechanically driven ejector by subcutaneous, intramuscular or intravenous injection. Alternatively, parenteral administration can be carried out by means of an infusion pump. The embodiments of the present disclosure provide pharmaceutical compositions suitable for administration to patients, wherein the administration includes administering a therapeutically effective amount of the composition of the present disclosure and one or more pharmaceutically acceptable excipients to patients in need thereof. Such pharmaceutical compositions can be prepared by any of various techniques using conventional excipients for pharmaceutical products well known in the art. (Remington's Pharmaceutical Sciences, 21st edition, University of the Sciences in Philadelphia, Philadelphia, PA, USA (2006)).
[0170] Selective Treg stimulatory composition (including RUR provided herein) 20kD -IL-2 and related compositions) and dosing regimens associated with the methods and compositions will vary depending on the age, weight and general condition of the subject and the type and state of the condition being treated, the judgment of the health care professional and the specific selective Treg stimulator composition to be administered.
[0171] As used herein, the term "effective amount" refers to the amount or dosage of the composition of the present disclosure that will induce a biological or medical response of a tissue, system, animal, mammal or human being sought by a researcher, veterinarian, doctor or other clinician after being applied to a patient or subject in a single dose or multiple doses, or the desired therapeutic effect on a tissue, system, animal, mammal or human being. Preferably, an effective amount refers to the amount or dosage of the composition of the present disclosure that will induce a selective Treg cell increase of at least 10 times the level before administration after being applied to a patient or subject in a single or multiple doses. The dosage may include a higher initial loading dose followed by a lower dosage. In one or more cases, a selective Treg stimulator composition (including RUR provided herein) 20kD-IL-2 and related compositions) is an amount encompassed by one or more of the following ranges expressed as the amount of IL-2: about 0.10 to about 700 μg / kg; about 0.20 to about 650 μg / kg, about 0.30 to about 600 μg / kg; about 1.0 to about 550 μg / kg, about 2.0 to about 500 μg / kg, about 10 to about 450 μg / kg, about 25 to about 400 μg / kg, about 50 to about 350 μg / kg or about 100 to about 300 μg / kg, including any and all combinations of the aforementioned starting and ending values from each and every of the aforementioned ranges. In some embodiments, for example, to treat an autoimmune disease in a subject or a disease or condition that can benefit from the preferential expansion and activation of regulatory T cells over conventional T cells and natural killer cells, a selective Treg stimulator composition (including RUR provided herein) 20kD -IL-2 embodiments and related compositions) are administered at a dose, for example, less than or equal to 500 μg / kg. A preferred dosage regimen of the present disclosure is one in which RUR is administered once every two weeks at a dose between 3-24 μg / kg 20kD -IL-2 and related compositions, and in particular those of formulation AE. Another preferred dosage regimen of the present disclosure is one in which RUR is administered once every two weeks at a dose between 3-18 μg / kg 20kD -IL-2 and related compositions, and in particular those of formulation AE. Another preferred dosage regimen of the present disclosure is one in which RUR is administered once every two weeks at a dose between 3-12 μg / kg 20kD -IL-2 and related compositions, and in particular those of formulation AE. Another preferred dosage regimen of the present disclosure is one in which RUR is administered once every two weeks at a dose between 3-6 μg / kg 20kD -IL-2 and related compositions, and in particular those of formulation AE. Another preferred dosage regimen of the present disclosure is one in which RUR is administered at a dose of 3 μg / kg once every two weeks 20kD - IL-2 and related compositions, and in particular those of formulations AE.
[0172] The compositions provided herein are effective in restoring the homeostatic capacity of the immune system, e.g., have the ability to positively impact diseases in which Treg dysfunction plays a role (such as autoimmune diseases, allergies, and transplant rejection). In one embodiment, provided herein is a method for treating a Treg stimulatory agent by administering a selective Treg stimulator composition (including RUR provided herein). 20kD-IL-2 embodiments and related compositions) selectively amplify endogenous Treg in vivo. Illustrative dosage ranges include, for example, about 100 μg / kg to about 500 μg / kg, or about 150 μg / kg to about 450 μg / kg, or about 175 μg / kg to about 400 μg / kg, or even about 175 μg / kg to about 350 μg / kg. Preferred dosages and dosing regimens are described in the embodiments provided herein. Suitable dosages effectively achieve maximum amplification of Treg cells, while stimulating Teff cells and NK cells minimally; This can be monitored as follows: peripheral blood is collected for flow cytometry analysis to identify the incidence of Treg cells, effector CD4+ and CD8+ T cells and NK cells. Based on these numbers, the dosage can be appropriately adjusted.
[0173] Dosage regimens may be adjusted to provide the optimum desired response (eg, therapeutic effect). For intravenous ( iv .) or non-intravenous administration, local or systemic or a combination thereof, with dosing schedules typically ranging from a single bolus dose or continuous infusion to multiple administrations per day (e.g., every 4-6 hours), or as indicated by the attending physician and the patient's condition. Regarding administration of a selective Treg stimulator composition (including RUR provided herein) 20kD-IL-2 embodiments and related compositions), a person of ordinary skill in the art can determine an appropriate dosing regimen. For example, during a treatment cycle, a clinician may decide to administer the composition as a single dose or a series of doses, for example, over the course of several days or weeks. Based on the long-acting properties of the composition, it is preferred that it is generally administered relatively infrequently (e.g., once every three weeks, once every two weeks, once every 8-10 days, once a week, etc.). Exemplary lengths of time associated with a course of therapy include about one week; about two weeks; about three weeks; about four weeks; about five weeks; about six weeks; about seven weeks; about eight weeks; about nine weeks; about ten weeks; about eleven weeks; about twelve weeks; about thirteen weeks; about fourteen weeks; about fifteen weeks; about sixteen weeks; about seventeen weeks; about eighteen weeks; about nineteen weeks; about twenty weeks; about twenty-one weeks; about twenty-two weeks; about twenty-three weeks; about twenty-four weeks; about seven months; about eight months; about nineteen months; about ten months; about eleven months; about twelve months; about thirteen months; about fourteen months; about fifteen months; about sixteen months; about seventeen months; about eighteen months; about nineteen months; about twenty months; about twenty-one months; about twenty-two months; about twenty-three months; about twenty-four months; about thirty months; about three years; about four years and about five years. The treatment methods described herein are generally continued for as long as the clinician supervising the patient's care deems the treatment method effective, i.e., the patient is responding to the treatment, or until the associated symptoms of the condition abate. Non-limiting parameters indicating that the treatment method is effective may include one or more of: increased numbers of regulatory T cells, such as CD25+ Tregs and FoxP3+ Tregs, and / or decreased numbers of NK cells and CD4+ and CD8+ effector cells.
[0174] When administered to a subject at a therapeutically effective dose, the compositions provided herein can be used to increase the ratio of regulatory T cells (such as Foxp3+ and CD25+ cells) to effector T cells (such as CD4+ and CD8+ cells). For example, when compared to a baseline and evaluated in an in vivo mouse model (e.g., such as described herein), a selective Treg stimulator composition (including RUR provided herein) can be used to increase the ratio of regulatory T cells (such as Foxp3+ and CD25+ cells) to effector T cells (such as CD4+ and CD8+ cells). 20kD -IL-2 and related compositions) can effectively cause regulatory T cells to increase by at least two times. In some embodiments, when compared with the baseline and evaluated in an in vivo mouse model (e.g., such as described herein), the method can also effectively cause regulatory T cells to increase by at least four times. In some cases, the increase in the number of regulatory T cells is maintained above the baseline level, and continues for at least 3 days after administration, or even continues for at least 5 days after administration.
[0175] As shown in the accompanying examples, when administered within an appropriate dosage range, the selective Treg stimulatory compositions (including RUR provided herein) 20kD-IL-2 embodiments and related compositions) effectively increase the cell population and immunosuppressive function of regulatory T cells preferentially, while minimizing the stimulation of T effector cells. In certain embodiments, the selective Treg stimulator composition (including RUR provided herein) 20kD -IL-2 embodiments and related compositions) enable sustained exposure for providing the magnitude, duration and specificity of Treg vs. Teff responses that cannot be achieved with equivalent doses of native IL-2. Example
[0176] It should be understood that the foregoing description and the following examples are intended to illustrate rather than limit the scope of the disclosure provided herein. Other aspects, advantages and modifications within the scope of the present disclosure will be apparent to those skilled in the art to which the present disclosure belongs.
[0177] Materials and methods
[0178] Cloning and expression of human interleukin-2 with a kinase activity similar to that of aldesleukin (des-alanyl-1, serine-125, see Figure 2 ) and used to prepare a recombinant human IL-2 referred to herein as RUR 20kD -IL-2 exemplary selective Treg stimulator composition. The sequence excludes amino acid #1 (alanine) from the naturally mature human IL-2 sequence, and there is an amino acid mutation from cysteine to serine at amino acid #125. The first amino acid in the sequence is methionine (uncoded signal peptide) for direct bacterial expression. After expression, the N-terminal methionine is removed by the host methionine aminopeptidase. A single disulfide bond is formed between the cysteine at amino acid positions #58 and #105. The protein is not glycosylated because it is derived from Escherichia coli. In some descriptions, the conjugated IL-2 composition can be described in some aspects as (1,3-bis (methoxy poly (ethylene glycol) aminoformyl) -2-propoxy) -4-butyramide) interleukin-2), noting that the nomenclature does not fully describe the PEGylation pattern or mixture.
[0179] Polyethylene glycol reagent, mPEG2(20kD)-butyric acid, N-hydroxysuccinimide ester (1,3-bis(methoxypoly(ethylene glycol) 10kD Carbamoyl)-2-propoxy)-4-succinimidyl butyrate (also referred to herein as mPEG2-ru-20KNHS) was prepared as described in Example 2 of U.S. Patent No. 7,887,789. Appearance: white to off-white granular powder; molecular weight (Mn) 18-22 kDa (due to polymer polydispersity). 1,3-bis(methoxypoly(ethylene glycol)) is shown below 10kDStructure of carbamoyl)-2-propoxy)-4-succinimidylbutyrate.
[0180]
[0181] Unless otherwise indicated, the selective Treg stimulatory compositions (including RUR provided herein) 20kD The concentrations, amounts, and dosing levels of the rIL-2 embodiments and related compositions are reported on a protein basis, which counts only the mass contributed by the protein component and not the mass contributed by the PEG moiety. By using a protein basis, even for mixtures of conjugated rIL-2 molecules with various degrees of PEGylation, the effective RUR used for calculation is 20kD The IL-2 composition also has a molecular weight of 15.3 kDa since only rIL-2 protein was counted.
[0182] RUR 20kD -IL-2 related compositions are PEGylated conjugate mixture compositions consisting of rhIL-2 (aldesleukin sequence) conjugated to multiple polyethylene glycol (PEG) moieties covalently bound to lysine groups. The number of PEG moieties per rhIL-2 molecule (PEGylation degree) is a distribution of 2 and 3 PEG moieties (di- or tri-PEGylated) per molecule, with minor species containing 1 PEG (single-PEGylated) and 4 PEG (tetra-PEGylated) and / or higher PEGylated molecules, resulting in an average of about 2.5 PEG moieties per rhIL-2. Each PEG moiety has a nominal molecular weight of 20 kDa, and rhIL-2 has a molecular weight of 15.3 kDa, resulting in RUR 20kD - The nominal molecular weight of IL-2 is 65 kDa.
[0183] Example 1
[0184] RUR 20kD - Preparation of IL-2 and related compositions
[0185] A stock solution of mPEG2-ru-20K NHS (100 mg / mL) was prepared in 2 mM HCl. A typical IL-2 PEGylation reaction was performed as follows: 115 mL of IL-2 (aldesleukin) stock solution (1.3 mg / mL) was transferred to a 250 mL plastic bottle and 15 mL of 0.5 MBicine ( N,N-bis (2-hydroxyethyl) glycine)), pH 9.2 and 0.5 mL water are added to the solution of IL-2. PEGylation is initiated by dropwise adding 19.5 mL of mPEG2-ru-20K NHS stock solution to the solution containing IL-2. The resulting reaction mixture contains 1 mg / mL IL-2, 50 mM Bicine and 10 molar equivalents of mPEG2-ru-20KNHS (with respect to protein) and has a pH of 8.7. The reaction is allowed to proceed for 40 min at ambient temperature under gentle stirring. The reaction is terminated by adding 2.2 mL acetic acid to reduce the reaction pH to 4.1.
[0186] The obtained IL-2 conjugate product was purified by cation exchange chromatography using SP FF Sepharose. After the conjugation reaction was completed, the reaction mixture was dialyzed against 20 volumes of 10 mM sodium acetate buffer (pH 4.0). The dialyzed sample was diluted with water 1:4 and loaded onto a column equipped with SP FF Sepharose resin. The buffer used for cation exchange chromatography is as follows: buffer A: 10 mM sodium acetate (pH 4.0), and buffer B: 10 mM sodium acetate, 1.0 M sodium chloride (pH 4.0). Before sample loading, the resin was washed with buffer B and balanced with buffer A. After loading, the resin was washed with 3 column volumes of buffer A. Conjugated and unconjugated IL-2 were eluted using a four-step gradient consisting of: 0 to 50% buffer B over 5 column volumes, 25% to 50% buffer B over 1 column volume, 50% buffer B over 1 column volume, 50% to 100% buffer B over 1 column volume, and 100% buffer B over 1 column volume at a flow rate of 28 cm / h. Fractions containing IL-2 conjugates with a degree of PEGylation (dP) of 2 and 3 (i.e., dimers and trimers) were identified by SDS-PAGE and pooled.
[0187] The fractions containing dimer and trimer merging were concentrated using an ultrafiltration chamber (Amicon) and nitrogen stirred. The composition of the final product was determined by RP-HPLC using the following mobile phase: A, 0.09% TFA / water, and B, 0.04% TFA / acetonitrile. Intrada WP-RP C18 posts (3 x 150 mm) were used, wherein flow velocity was 0.5 ml / min, and column temperature was 50 ° C. The conjugate mixture determined to contain about 4.6% (mol) of single-PEGylated rIL-2, about 47.7% (mol) of di-PEGylated rIL-2, about 42.9% (mol) of three-PEGylated rIL-2 and about 4.8% (mol) of tetra-PEGylated IL-2. Referring to Fig. 1, elution time is provided on the x-axis. The average PEGylation degree of the final product mixture is determined to be 2.48 (that is, about 2.5). Free IL-2 was not detected in the final product mixture. This preparation is the RUR of formula A 20kD - An example of a composition of IL-2.
[0188] Example 1-A
[0189] RUR 20kD -Alternative preparation of IL-2 and related compositions
[0190] Expected RUR 20kD The preparation of IL-2 and related compositions consists of fermentation and purification of rhIL-2 protein process intermediates, conjugation of rhIL-2 with the PEG reagent starting material mPEG2-ru-20K NHS, purification of the IL-2 conjugate fraction with a specified degree of PEGylation, and final formulation of the PEGylated rhIL-2 conjugate to produce the desired distribution of RUR according to the embodiments described herein 20kD -IL-2 composition.
[0191] Expected RUR 20kD -IL-2 composition is prepared by: 1,3-bis(methoxypoly(ethylene glycol) 10kD Carbamoyl)-2-propoxy)-4-succinimidylbutyrate (also referred to herein as mPEG2-ru-20K NHS) reacts with lysine residues on the interleukin 2 (IL-2) protein (aldesleukin sequence) to result in a distribution of PEGylated IL-2 conjugates. The product contains primarily di-PEGylated and tri-PEGylated species with lesser amounts of mono-PEGylated and / or tetra-PEGylated species.
[0192] The frozen IL-2 starting material (purified recombinant IL-2 (aldesleukin sequence) in 10 mM acetate, 5% trehalose, pH 4.5 buffer stored at -70°C) was thawed to room temperature. The PEG reactant mPEG2-ru-20K NHS (powder) was dissolved by adding to a 2mM HCl solution at room temperature at ~90 g / L and stirred for a minimum of 15 minutes. The solution was then loaded into a reaction vessel. The thawed IL-2 was added to the reaction vessel, appropriately diluted with water, and then 0.75 Mbicine pH 9.7 buffer was added. The final IL-2 concentration in the reaction mixture was approximately 1.0 g / L, and the bicine concentration was approximately 50 mM to achieve a target pH of 8.7. Typically, in a bicine buffer solution of pH 8.5 to 9.5, the PEG:rhIL-2 mass ratio is about 10:1 to 13:1 to PEGylate the protein. The reaction was incubated at 22°C with continuous stirring for 40 minutes, as measured from the completion of the addition of the mPEG2-ru-20K NHS solution. At the end of the incubation period, the reaction was quenched by adding 1N acetic acid to rapidly lower the pH, and then immediately further titrated to pH 4.0 using additional 1N acetic acid. The quenched reaction was diluted 10-fold by adding water. The diluted quenched reaction was filtered through a 0.22 μm filter to provide a crude product.
[0193] The crude product is then subjected to SP SEPHAROSE® fast-flow cation exchange chromatography to partially separate the PEGylated reaction fractions. The SP SEPHAROSE® fast-flow cation exchange chromatography column is balanced and loaded with feed at room temperature, with a residence time of ~5 minutes, followed by washing 5 CV (column volume) with loading buffer. PEGylated rhIL-2 binds to resin, and free PEG is washed away. The product is then eluted with 0-500 mM sodium chloride in a 10 mM sodium acetate pH 4.0 buffer background using a linear gradient elution. The fractions of 0.15 CV each are collected, and ~1 CV is entered into elution. When the absorbance at 280 nm is <5% of the maximum peak, fraction collection is terminated. The PEGylated fraction concentration in each fraction (i.e., mono-PEGylated IL-2 (monomer), di-PEGylated IL-2 (dimer), tri-PEGylated IL-2 (trimer), tetra-PEGylated IL-2 (tetramer), etc.) is measured by the absorbance at a wavelength of 280 nm. The distribution of PEGylated fractions was measured by RP-HPLC as described herein, and fractions containing mono-PEG, di-PEG, tri-PEG and higher components were identified and used to determine the fraction distribution profile that would have the desired PEGylation (e.g., RUR provided herein). 20kDRecombination of the fractions necessary for the composition of the invention (e.g., di-PEG-IL-2 and tri-PEG-IL-2, and / or mono-PEG or higher PEG) is calculated to achieve the target profile as provided herein, and then recombined as needed to obtain a product with the desired PEGylated fraction distribution. 20kD -IL-2 composition. Alternatively, a purification scheme can be designed so that elution and collection can provide the desired profile according to the embodiments described herein without re-combining. The desired (and / or re-combined) chromatographically purified preparation is then concentrated and diafiltered into 10 mM sodium acetate, 150 mM sodium chloride, 2% w / v sucrose, pH 5.0 using tangential flow filtration (TFF) to achieve a RUR of 1 mg / mL (based on protein) 20kD - The final target concentration of the IL-2 composition drug substance.
[0194] The recombined and / or target products were analyzed and the composition distribution was verified by the methods described herein (including RP-HPLC) to evaluate the profile of the PEG fraction. The RUR of Formula AE according to the specification herein is exemplified by the example product batches numbered 1-4 listed in Table 1 below. 20kD - Preparation of the composition of the IL-2 composition. The determination of properties is known to the skilled person and / or is described in Example 1-B to Example 1-I or in other descriptions herein. An appropriate historical reference sample composition is established and used for comparison in subsequent preparations.
[0195] Table 1. RUR by RP-HPLC and SEC-HPLC 20kD - Overview of illustrative analysis of samples from different batches of IL-2 composition
[0196]
[0197] ND is not detectable and NMT is not exceeded.
[0198] In some embodiments, on a molar basis, the RUR 20kD -The IL-2 composition product will contain less than 1% free, unconjugated IL-2 (more preferably no detectable free IL-2), 5% or less mono-PEGylated IL-2, about 28% to about 60% di-PEGylated IL-2, about 24% to about 65% tri-PEGylated IL-2, 12% or less higher-PEGylated IL-2 species, and 80% or more combined di- and tri-PEGylated IL-2 species.
[0199] In some embodiments, the RUR 20kD -IL-2 composition product will contain, for example, less than 0.5 mol % of free IL-2, about 2.5 to about 4.5 mol % of mono-PEGylated IL-2, about 35 to about 50 mol % of di-PEGylated IL-2, about 38 to about 46 mol % of tri-PEGylated IL-2, about 3 to about 10 mol % of higher PEGylated IL-2 species, and about 80 to about 95 mol % of the combined total amount of di-PEGylated and tri-PEGylated IL-2.
[0200] In some embodiments, on a molar basis, the RUR 20kD -IL-2 composition product will contain, for example, 5% or less mono-PEGylated IL-2, and 28% to about 60% di-PEGylated IL-2, and about 24% to about 65% tri-PEGylated IL-2, and about 12% or less of higher PEGylated IL-2 species. Preferably, the composition contains 80% or more of the combined di- and tri-PEGylated IL-2 species.
[0201] In some embodiments, the RUR 20kD -IL-2 composition product will contain, for example, about 2.5 to about 4.5 mol % of mono-PEGylated IL-2, and about 35 to about 50 mol % of di-PEGylated IL-2, and about 38 to about 46 mol % of tri-PEGylated IL-2, and about 3 to about 10 mol % of higher PEGylated IL-2 species. Preferably, the composition comprises a combined total amount of about 80 to 95 mol % of di-PEGylated and tri-PEGylated IL-2.
[0202] In some embodiments, the RUR 20kD -IL-2 composition product will contain, for example, about 2.8 to about 3.8 mol % of mono-PEGylated IL-2, and about 44 to about 48 mol % of di-PEGylated IL-2, and about 41 to about 44 mol % of tri-PEGylated IL-2, and about 7 to about 9 mol % of higher PEGylated IL-2 species. Preferably, the composition comprises a combined total amount of about 87 to 90 mol % of di-PEGylated and tri-PEGylated IL-2.
[0203] In some embodiments, the RUR 20kD-IL-2 composition product will contain, for example, about 2.8 to about 3.8 mol% of mono-PEGylated IL-2, and about 44 to about 48 mol% of di-PEGylated IL-2, and about 41 to about 44 mol% of tri-PEGylated IL-2, and about 7 to about 9 mol% of higher PEGylated IL-2 species, and wherein the composition comprises a mixture of mono-PEGylated IL-2 conjugates having a PEG moiety attached at one of lysines K7 or K8 or K31 or K75. Preferably, the composition comprises a combined total amount of about 87 to 90 mol% of di-PEGylated and tri-PEGylated IL-2.
[0204] In some embodiments, the RUR 20kD -IL-2 composition product will contain, for example, about 2.8 to about 3.8 mol% of mono-PEGylated IL-2, and about 44 to about 48 mol% of di-PEGylated IL-2, and about 41 to about 44 mol% of tri-PEGylated IL-2, and about 7 to about 9 mol% of higher PEGylated IL-2 species, and wherein the composition comprises a mono-PEGylated IL-2 conjugate having a PEG moiety attached at lysine K7. Preferably, the composition comprises about 87 to 90 mol% of the combined total amount of di-PEGylated and tri-PEGylated IL-2.
[0205] Example 1-B
[0206] RUR by reverse phase HPLC 20kD - Purity and characterization of IL-2 compositions
[0207] RUR was evaluated by reverse phase high performance liquid chromatography (RP-HPLC) using an Agilent 1200 series instrument equipped with a diode array detector (UV at 215 nm). 20kD -Chromatographic purity and identity of samples of IL-2 compositions. The column used can be an ACE 3 Phenyl-300 column (Mac-Mod Analytical Inc.) (or other suitable column) with an eluent flow rate of 0.6 mL / min. RP-HPLC is performed using a gradient containing a mixture of the following two mobile phases: (1) mobile phase A, a solution of 0.1% formic acid in water, and (2) mobile phase B, a solution of 0.1% formic acid in acetonitrile. The linear gradient range is 60% mobile phase A / 40% mobile phase B to 40% mobile phase A / 60% mobile phase B, to 20% mobile phase A / 80% mobile phase B, to 60% mobile phase A / 40% mobile phase B. The components of the diluent / formulation buffer are 10 mM sodium acetate, 200 mM sodium chloride, 2% sucrose, and pH 5.0.
[0208] The frozen RUR 20kD - IL-2 composition reference materials and samples were thawed and diluted to 1.0 mg / mL with formulation buffer. At least one blank control of formulation buffer was first subjected to RP-HPLC via injection to ensure no interference with RUR 20kD -IL-2-composition related peaks. Next, RUR 20kD -IL-2 composition reference material or control injected five times. Next, inject RUR 20kD -IL-2 composition sample. After every six sample injections and at the end of the injection sequence, inject RUR 20kD - IL-2 composition reference material / control.
[0209] Contains di-PEGylated (di-PEG) and tri-PEGylated (tri-PEG) RUR 20kD - The % relative standard deviation (RSD) of the retention time of the first five reference material injections of the IL-2 composition does not exceed 2.0%. All reference material RURs for di-PEG and tri-PEG components 20kD - The %RSD area percentage of the IL-2 composition injection did not exceed 5.0%. All RURs from the reference and sample injections were 20kD - IL-2 composition peak integration. Specifically, for a 1.0 mg / mL concentration of RUR 20kD -IL-2 composition, respectively, di-PEG and tri-PEG RUR above the 0.5% detection limit (LOD) 20kD -IL-2 composition type and rhIL-2 peak integration above 0.3% LOD. For RUR concentration of 1.0 mg / mL 20kD -IL-2, limit of quantification (LOQ) for di-PEG and tri-PEG RUR 20kD - 1.0% for IL-2 species and 0.5% for rhIL-2. The results from the analysis are shown below in Table 2 (6 samples) and Table 3 (12 samples).
[0210] Table 2: Six RURs analyzed by RP-HPLC 20kD - Area percentages of mono-PEG, di-PEG, tri-PEG, tetra-PEG, and penta-PEG fractions of replicate samples of IL-2 composition
[0211]
[0212] Table 3: Twelve RURs analyzed by RP-HPLC 20kD- Area percentages of mono-PEG, di-PEG, tri-PEG, tetra-PEG, and penta-PEG fractions of replicate samples of IL-2 composition
[0213]
[0214] Example 1-C
[0215] RUR by size exclusion HPLC 20kD - Purity and characterization of IL-2 compositions
[0216] Size exclusion high performance liquid chromatography (SEC-HPLC) was also used to determine the purity and characterize RUR using an Agilent 1200 series instrument equipped with a diode array detector (UV at 280 nm) and a YarraSEC-2000 column (Phenomenex). 20kD -IL-2 composition, and the eluent flow rate was 0.225 mL / min. The mobile phase was 0.2 M ammonium acetate (pH 5.5) in a volume ratio of 80:20 to acetonitrile. The diluent / formulation buffer contained 10 mM sodium acetate, 200 mM sodium chloride, 2% sucrose, pH 5.0. The frozen RUR 20kD -IL-2 composition reference material and analytical samples were thawed and diluted to 1.0 mg / mL with formulation buffer. The samples were stable in solution at 5°C for up to 5 days.
[0217] Procedurally, at least one blank control of formulation buffer was first subjected to RP-HPLC via injection to ensure no interference with the RUR 20kD -Analysis of IL-2-related peaks. Next, RUR was injected 20kD -IL-2 composition, system suitability solution to ensure that from tetra-PEG RUR 20kD - IL-2 fraction was resolved into aggregates or higher molecular weight species. 20kD -IL-2 composition reference material or control injected five times. Next, inject RUR 20kD -IL-2 composition sample. After every six sample injections and at the end of the injection sequence, inject RUR 20kD - IL-2 composition reference material / control.
[0218] Di-PEG and tri-PEG RUR of the first five injections of the reference material 20kD -% RSD of retention time of IL-2 fraction did not exceed 2.0%. Di-PEG and tri-PEG RUR for all reference material injections 20kD - The %RSD area percentage of IL-2 does not exceed 5.0%. All RURs from reference and sample injections20kD - IL-2 fraction peak integration. Specifically, for a 1.0 mg / mL concentration of RUR 20kD -IL-2 composition, di-PEG and tri-PEG RUR above 1.0% detection limit (LOD) 20kD -IL-2 fraction integration. For RUR at 1.0 mg / mL 20kD -IL-2, only di-PEG and tri-PEGRUR reported above 3.0% LOQ 20kD -IL-2.
[0219] RUR 20kD -Analysis of replicate samples of the IL-2 composition is shown in Tables 4 and 5 below, where the RUR 20kD - Peak areas of mono-PEG, di-PEG, tri-PEG, tetra-PEG and penta-PEG fractions of IL-2 compositions.
[0220] Table 4: RUR by SEC-HPLC 20kD -Peak area % of mono-PEG, di-PEG, tri-PEG, tetra-PEG and penta-PEG components of IL-2
[0221]
[0222] Table 5: RUR by SEC-HPLC 20kD - Peak area % of mono-PEG, di-PEG, tri-PEG, tetra-PEG and penta-PEG fractions of IL-2 composition samples
[0223]
[0224] RUR by both RP-HPLC and SEC-HPLC 20kD An overview of representative analyses of different samples of -IL-2 compositions is shown in Table 1. As can be seen, RUR 20kD - IL-2 composition formulations demonstrated good batch-to-batch consistency with respect to the mixture of PEGylated fractions (ie, mono-PEGylated, di-PEGylated, tri-PEGylated, tetra-PEGylated, penta-PEGylated, etc.).
[0225] Example 1-D
[0226] SDS-Page
[0227] SDS-PAGE was used to confirm the RUR 20kD -IL-2 composition identity. 20kD -IL-2 composition, molecular weight markers and appropriate RUR 20kD-IL-2 composition reference material sample is loaded on NuPAGE Bis-Tris gel, and by gel migration.After electrophoresis, use GelCodeTM Blue Safe Protein Stain to dye the gel.Comparison of gel migration banding pattern and reference material and confirmation of no new bands in sample confirm the identity of sample.The two strongest bands will correspond to the fraction of tri-PEGization and di-PEGization.The top band in the lane corresponds to the variant of higher PEGization, and the lowest band corresponds to the variant of single-PEGization.
[0228] Example 1-E
[0229] Affinity for IL-2Rαβ using surface plasmon resonance (SPR), and efficacy in U-2 OS cells expressing the human IL-2Rαβα complex.
[0230] RUR was measured using Biacore X-100 surface plasmon resonance with polarized light detection 20kD -IL-2 composition binding affinity. The technology involves activating the surface of a Biacore CM5 sensor chip with a 1:1 complex of N-hydroxysuccinimide 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (NHS EDC) to generate active NHS esters. Goat anti-human Fc antibodies in sodium acetate, pH 4.0 buffer were covalently attached to the surface of the chip. Residual NHS esters were quenched with 1M ethanolamine. A 1:1 mixture of IL-2-Rα-Fc (human IL-2Rα-Fc chimera; Symansis) and IL-2Rβ-Fc (human IL-2Rβ-Fc chimera; Symansis) was captured on the chip using HBS-EP buffer (1mM HEPES, pH 7.4, 15mM NaCl, 0.3mM EDTA, 0.0005% v / v surfactant P20) with 0.1% BSA. RUR 20kD -IL-2 composition was serially diluted in HBS-EP buffer with 0.1% BSA and injected on the sensor chip. The kinetic binding affinity was measured by applying the solution for 3 minutes (kon) followed by a 3-minute wash (koff). The ratio between koff and kon was used to calculate the kinetic binding affinity KD. 20kD The results of triplicate analyses of the IL-2 composition are listed in Table 6. The binding affinity and rate were consistent for both drug substance lots.
[0231] Table 6: RUR using SPR 20kD - Binding affinity of IL-2 compositions to IL-2Rαβ
[0232]
[0233] Alternatively, PathHunter ® The platform, a cryopreserved, ready-to-use cell-based assay format, provides a more robust and consistent cellular response than that of cultured cells. Enzyme (β-galactosidase) fragment complementation assay (PathHunter from DiscoverX Corporation, CA) ® The RUR was measured in U-2 OS cells expressing the human IL-2Rαβα complex. 20kD -The efficacy of IL-2 combination. The basis of this assay utilizes isolated enzyme fragments, which are inactive when isolated. The two enzyme fragments are fused to the intracellular domain of the IL-2Rβ or IL-2Rγ subunit, and after the interaction of the ligand with the receptor, the receptor subunits are brought into close proximity to restore enzyme activity. With the addition of substrate, the enzyme acts and produces a luminescent signal. After incubating the sample and reference with the cells for ~6 hours, the receptor activation via enzyme fragment complementation is measured. RUR 20kD -IL-2 compositions provide low-dose signaling through the high-affinity heterotrimeric αβγ IL-2 receptor (IL-2R).
[0234] Example 1-F
[0235] RUR 20kD -PEGylation site occupancy of IL-2 compositions
[0236] Direct comparison of RUR by peptide mapping 20kD -IL-2 composition and rhIL-2 to characterize RUR from two batches 20kD -PEGylation site occupancy of IL-2 composition. 20kD In the RUR20kD-IL-2 digest, lysine-containing peptides can be PEGylated and reflected by their corresponding native lysine-containing peptides having lower abundance (compared to the same peptides in the reference rhIL-2 digest). Therefore, the PEGylation site occupancy can be calculated based on the reduced abundance of native peptides in the RUR20kD-IL-2 digest analyzed. In addition, peptide mapping of alternative materials can be used to additionally confirm site occupancy.
[0237] In general, this analysis can be performed as follows. In direct peptide mapping comparative studies, RUR 20kD - IL-2 composition and rhIL-2 reference control samples were simultaneously digested by GluC and GluC / trypsin followed by LC-UV / MS / MS analysis to provide peptide identification and abundance. 20kD- Peptide mapping comparison of IL-2 compositions and rhIL-2 was used to determine PEGylation site occupancy.
[0238] In short, in RUR 20kD -IL-2 composition and rhIL-2 are analyzed by selecting one or more common peptides without lysine as one or more references. The relative intensity of the peptide is the normalization of one or more references. The relative abundance of natural peptides (RR) with lysine is reduced and calculated by the relative intensity of the peptide (Formula 1). The PEGylation site occupancy at lysine is the average RR from the peptide containing lysine.
[0239]
[0240] Peptide relative intensity (Pep / Ref) = UV peak area (peptide) / UV peak area (reference peptide).
[0241] Use as RUR 20kD -IL-2 surrogate material is a product produced by conjugating monodisperse 4kD PEG to the lysine of rhIL-2. 20kD -PEGylation profile of IL-2 compositions, using the same conjugation linker to prepare alternatives and in the preparation of RUR 20kD The conjugation reaction was carried out under the same reaction conditions as the IL-2 composition. LCMS / MS-based GluC mapping and trypsin mapping of the surrogate identified the PEGylated lysine and RUR 20kD -IL-2 provides supporting information.
[0242] RUR 20kD -GluC profile of IL-2 (GMP batch) with 95% coverage of rhIL-2 sequence. 20kD Direct comparison of the GluC profiles of IL-2 and rhIL-2 provides a new insight into the potential of RUR 20kD - Relative quantification of 4 of the 11 lysines in IL-2 (see Table 7), with lysines 7 and 8 counted as one site in the peptide map. Peptides containing the remaining lysines in the GluC map showed evidence of PEGylation with no site differences. Additional trypsin cleavage of the lysine-containing peptides in the GluC / trypsin map provided PEG occupancy at K31, K34, K42, and K47. 20kD - Comparison of the GluC / Trypsin mapping chromatograms of IL-2 and rhIL-2 showed a significant reduction of those peptides (see Table 7). Due to enzymatic mis-cleavage, no PEGylation occupancy of the K48 site was available in the Trypsin / GluC profile (N / A).
[0243] Peptide mapping of 4k PEGylated rhIL-2 surrogates identified peptides with 4k PEG labeled lysine with high mass accuracy (<5 ppm). 20kD The combined results of direct peptide mapping of IL-2 and 4k PEGylated rhIL-2 surrogates showed that K7, K31 and K75 are the major PEGylation sites (see Table 8). 20kD - Less important PEGylation sites of the IL-2 composition may be K8, K34, K42, K47, K53 and K63. K48 may be PEGylated, while K96 is undetermined.
[0244] In the second RUR 20kD - PEGylation site occupancy was comparable in the GMP formulation of the IL-2 composition and in the development batches (see Table 7). The combined approach of GluC mapping and trypsin / GluC mapping was RUR 20kD -Some major PEGylation sites of the conjugates in the IL-2 composition provide batch-to-batch information.
[0245] Table 7.
[0246] RUR 20kD -PEGylation site occupancy in IL-2 compositions: GMP and DEMO batches
[0247]
[0248] DEMO batch refers to the preparation carried out to prove the operability of the production process.
[0249] Table 8. RUR 20kD - Overview of PEGylation site occupancy in IL-2 compositions and 4k PEGylated rhIL-2 alternatives
[0250] Major PEG sites from direct digestion (GluC and GluC / trypsin profiles) Major PEGylated rhIL-2 sites from alternative PEGylation (GluC and trypsin maps) Major PEG sites from combined results K7 / K8 K7 K7 K31 K31 K31 K34 (possibly) K34 (not preferred) N\A K48 (Unknown) K48 K48 (possibly) K75 K75 K75
[0251] Example 1-G
[0252] RUR 20kD - Solution Phase Stability of IL-2 Compositions
[0253] The RUR of 1.0 mg / mL was evaluated at 1, 3, 5, and 7-day time points under three different storage conditions (room temperature (ambient laboratory conditions), 5°C (refrigerated), and -20°C) by RP-HPLC as previously described. 20kD - Stability of solutions of IL-2 compositions (rhIL-2 equivalent of -1 mg / mL in 10 mM sodium acetate, 200 mM sodium chloride (pH 5) containing 2% (w / v) sucrose).
[0254] For control, freshly prepared RUR 20kD -IL-2 composition sample solution evaluation RUR 20kD - Differences between IL-2 composition solutions. RUR stored at room temperature, 5°C and -20°C for up to 7 days 20kD - The di-PEG and tri-PEG species of the IL-2 composition samples showed up to 1% relative differences compared to the nominal -70°C sample storage. 20kD The relative differences (Rel. Diff.) of the minor percentage component PEGylation species (mono-PEG, tetra-PEG and penta-PEG species) of -IL-2 were up to 8%. This indicates that the solution samples stored under these representative storage conditions are stable.
[0255] In vitro bioassay:
[0256] In vitro methods can be used to further measure RUR 20kD - Biological efficacy and biological characterization of IL-2 compositions, including cell-based assays to characterize biological activity following activation of receptors that are representative of the IL-2 receptor complex:
[0257] Table 9: Bioassay methods
[0258]
[0259] In all three assays, data from dose-response curves (response versus concentration) were evaluated using nonlinear regression models. 20kD - The efficacy of the IL-2 composition samples was measured by the half maximal effective concentration (EC 50 ) ratios are measured relative to a reference material.
[0260] Example 1-H
[0261] CTLL-2 cell proliferation assay
[0262] In the cell proliferation assay, cell growth was measured in vitro using CTLL-2 cells after incubation of samples and references for ~26 hours, where cell proliferation was measured via a luminescent ATP-based assay (CellTiter-Glo ® , Promega, WI). For example, this cell-based proliferation assay uses the CTLL-2 cell line, which exhibits a dose-dependent proliferation response to rhIL-2 protein. rhIL-2 is used as an assay control, and in this method, different concentrations of rhIL-2 are measured from RUR 20kD -IL-2 composition preparation. The assay was performed in a 96-well plate format. CTLL-2 cells were starved for rhIL-2 in starvation medium and cultured at 37°C and 5% CO2 Incubate overnight in an incubator for 20 ± 3 hours. Starved cells were plated in 96-well plates and RUR 20kD - A dilution series of IL-2 composition was fed to the cells and incubated at 37°C and 5% CO 2 Incubate in the incubator for another 25 ± 3 hours. Measure the RUR in each well using Promega's CellTiter Glo® Assay Kit. 20kD -IL-2 composition-induced cell growth. CellTiter Glo® generates a luminescent signal proportional to the amount of ATP present in each well, which is directly proportional to the viable cells present. The luminescent signal is read on a SpectraMax M5 plate reader. RUR is generated by plotting the fluorescent signal (y-axis) against the concentration (x-axis) 20kD -IL-2 composition reference material and dose response curve of each sample.The figure was fitted to a 4-parameter logistic nonlinear regression model.Parallel lines analysis (PLA) software was used to evaluate the equivalence test for slope differences (parallelism), the significance of regression, and to calculate the efficacy ratio of the sample relative to the reference material in the same plate.
[0263] Embodiment 1-I
[0264] Phosphorylation-STAT5 activation
[0265] In the phosphorylated-STAT5 assay following receptor binding, downstream cell signaling can then activate Signal Transducer and Activator of Transcription 5 (STAT5) via phosphorylation to promote gene expression to induce cell proliferation. In CTLL-2 cells (an IL-2-dependent murine T lymphocyte cell line), phosphorylated-STAT5 / total STAT5 multiplex assay (Meso Scale Discovery, MD) was used to measure the activation of phosphorylated-STAT5 in response to sample and reference treatment for ~10 minutes.
[0266] Example 2
[0267] In vivo studies: single-dose PK / PD studies in mice
[0268] RUR can be demonstrated in mice 20kD -Selective stimulation of Tregs by IL-2 compositions. RUR was administered to C57BL / 6 mice (n=4 / group) at doses of 0.03, 0.1, and 0.3 mg / kg. 20kD- Single subcutaneous administration of IL-2 composition. After administration, blood and spleen samples were collected on days 1-7 and 10 after administration. More specifically, at each time point, blood and spleen samples were collected; samples were combined and evaluated by flow cytometry for pharmacodynamic analysis of drug effects on lymphocyte cell populations (see, e.g., Example 5), expressed as a multiple change relative to vehicle control. In addition to changes in cell number, markers of function and activity were quantitatively evaluated. Finally, plasma drug concentration was also evaluated.
[0269] like Figure 3A and 3B As shown in 20kD -Administration of IL-2 composition resulted in a decrease in CD4 + There was a dose-dependent increase in Tregs, with the increase in cell numbers reaching a peak four days after administration. At the highest dose tested (0.3 mg / kg), a sustained effect on Treg mobilization was achieved, with Treg levels not returning to baseline until 7-10 days after administration. In the blood, NK cells were elevated after administration of the highest dose tested, while changes in CD4 T cells were modest and CD8 T cells decreased slightly ( Figure 4A -C). B cells and CD8 T cells decreased slightly after administration of the highest dose tested (a dose that also resulted in a less than 2-fold increase in NK cells). Markers of Treg function and activity ( Figure 5A and 5B ) showed that at the highest dose tested, RUR 20kD - Administration of the IL-2 composition resulted in an increase in Treg activation, as measured by the mean fluorescence intensity (MFI) of CD25 and Foxp3. Although Treg numbers did not reach a maximum until four days after administration, these activation markers reached their maximum within the first two days after administration, according to the RUR 20kD -IL-2 plasma exposure and slowly decreased. The percentage of rapidly proliferating Tregs as measured by Ki67 rose rapidly two days after administration, and the percentage remained maintained until the 6th day, then returned to baseline levels. In addition, the percentage of Tregs expressing the cell surface marker inducible T cell co-stimulator (ICOS) also increased, which is a notable finding because ICOS expression is associated with increased inhibitory activity of Tregs in an autoimmune environment. Although the increase in Ki67 and ICOS appears to be relative to the peak RUR 20kD -IL-2 composition concentrations were somewhat delayed, but their return to baseline levels did coincide with a decrease in plasma concentrations in this preclinical mouse study.
[0270] Example 3
[0271] In vitro Treg suppression assay
[0272] The goal of this study was to evaluate the suppressive function of regulatory T cells. 20kD - IL-2 composition treated C57BL / 6 mice magnetically isolated Treg. Treg and Tcon were co-cultured for three days at a ratio ranging from 1:2 to 1:512. 3 Cell proliferation was assessed by addition of H-thymidine, and the % of proliferating cells relative to the plate control was calculated.
[0273] Briefly, RURs were obtained from the various dose levels (0.03, 0.1, and 0.3 mg / kg) at the indicated times after dosing. 20kD -IL-2 compositions or vehicle-treated female C57BL / 6 mice collect spleen (n=4 mice / treatment group / time). For each spleen, single cell isolates are prepared, and the resulting splenocyte mixture is combined for each dosage group at each time point. The combined sample is equivalent to a portion of a spleen and is divided equally for immune cell profiling. The remaining splenocyte preparation is used to separate regulatory T cells (Treg). According to the manufacturer's advice, CD4+CD25+ Treg is separated from mouse spleen by magnetically activated cell sorting (MACS) utilizing CD4+CD25+ regulatory T cell separation mouse kit (Miltenyi Biotec, Bergisch Gladbach, Germany). CD4+T cells are negatively selected and then divided into CD4+CD25-T cells and CD4+CD25+ Treg. Naive conventional CD4+CD25- T cells (Tcon) were isolated from mouse spleens harvested from naive animals by MACS using a Naive CD4+ T Cell Isolation Kit (Miltenyi Biotec) following the manufacturer's recommended procedures.
[0274] In vitro inhibition assays were performed in RPMI1640 medium supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 0.5 μM β-mercaptoethanol, and 1X antibiotic / antimycotic (100 units / mL penicillin, 100 μg / mL streptomycin, and 250 ng / mL amphotericin B). 5 x 10 4Each Tcon was used to stimulate the beads coated with anti-CD3 and anti-CD28 (T cell activation / amplification kit, mouse, Miltenyi Biotec) at a ratio of 2 beads: each Tcon. The inhibitory ability of Treg was evaluated by adding Treg to Tcon at different ratios (2:1 to 1:512 Treg:Tcon ratio). Each Treg:Tcon ratio was tested in triplicate. The cells were incubated in a humidified atmosphere at 37 ° C and 5% CO 2 16 hours before the assay was terminated, 0.5 μCi [3H]-thymidine was added to the wells. After the cells were washed out of the unincorporated [3H]-thymidine, thymidine uptake was measured as counts per minute (CPM) using a microplate scintillation counter (TopCount NXT, PerkinElmer). Individual CPM values were normalized for maximum proliferation by dividing by the average CPM recorded for the four lowest Treg:Tcon dilutions. In Prism® 6.03 (GraphPad Software, San Diego, California), concentration-response curves were drawn using four-parameter nonlinear regression and 1 / y2 weighting.
[0275] As shown in Figures 6A-D, Tregs isolated from the spleen of vehicle-treated mice at 1 and 4 days after the start of the study exhibited suppressive capacity, with maximal suppression occurring at a 1:2 ratio. 20kD -IL-2 composition at these time points isolated Tregs exhibited greatly increased suppressive capacity, as evidenced by reduced Tcon proliferation, especially at ratios greater than 1:8. The relative suppressive capacity of isolated Tregs cultured with Tcon at a ratio of 1:2 was also evaluated over time ( Figure 7 ). 20kD - The increased Treg suppressive activity was maintained for four days following IL-2 administration before returning to the baseline activity exhibited by the vehicle control treated group.
[0276] Example 4
[0277] RUR in the mouse KLH DTH efficacy model 20kD - Evaluation of IL-2 composition
[0278] In order to 20kD -IL-2 compositions were evaluated for their ability to suppress T-cell antigen-driven inflammation in a model of delayed-type hypersensitivity (DTH) using Balb / c mice (n=6-10 / group). Mice were sensitized subcutaneously in their dorsal region with a 100 µl subcutaneous injection containing 100 µg keyhole lipoprotein in an emulsion. Hemocyanin (KLH), the emulsion contained complete Freund's adjuvant (CFA) and incomplete Freund's adjuvant in a ratio of 1:1:1, respectively. Five days later, baseline ear thickness was measured before subcutaneous challenge with 10 μg KLH in the left ear, with the right ear remaining untreated. In all groups, ear thickness measurements were measured with a caliper at 24, 48, 72, and 96 hours after KLH challenge. RUR 20kD - IL-2 composition was administered on day 0, at the time of sensitization, with subcutaneous doses ranging from 0.003 mg / kg to 0.3 mg / kg every three days. A positive control consisting of cyclosporine (10 mg / kg, single dose) was administered on day 0.
[0279] like Fig. 8A , 8B As shown in , after antigen challenge, ear swelling was induced, with the average increase in ear thickness reaching a maximum of over 14 mm at 48 hours. Untreated, unchallenged ears showed no change in thickness during the course of the study. RUR throughout the sensitization and challenge periods in this study 20kD Administration of the IL-2 composition resulted in a significant dose-dependent reduction in ear swelling, as evidenced by a reduction in inflammation relative to vehicle control at each time point. To more quantitatively assess the effect after challenge, the AUC of the change in thickness (AUC 0-96h ).like Fig. 8A and 8B As shown in , the minimum effective dose is 0.01 mg / kg q3d, while the maximum effect is achieved with 0.3 mg / kg q3d. Statistically significant AUC values from the vehicle group are indicated with an asterisk ( p <0.05; ANOVA, Tukey's). Taken together, this data suggests that the enhanced mobilization and activation of Tregs achieved after administration can suppress antigen-driven inflammatory mechanisms in vivo.
[0280] Evaluation of the RUR of Example 1 after in vivo administration in rodents and cynomolgus monkeys 20kD -IL-2 combination activity. In mice, RUR 20kD -IL-2 combination resulted in a dose-dependent increase in Tregs, which reached a maximum four days after administration. 20kD -Flow cytometric analysis of Tregs induced by the IL-2 composition showed that the mean fluorescence intensity (MFI) of markers of Treg activation, such as Foxp3 and CD25, reached its maximum within the first two days of administration and increased according to RUR 20kD-The plasma exposure of the IL-2 composition gradually decreased over time. The percentage of actively proliferating Tregs also reached its maximum within 2 days after administration and was maintained until day 6. The expression of ICOS, a marker of Treg function, peaked on day 3 and then returned to baseline by day 7. Tregs isolated from the spleen of treated mice greatly increased their suppressive capacity within the first four days after administration and then returned to baseline activity levels. When administered every three days, the RUR of Example 1 20kD - IL-2 compositions inhibit antigen-driven inflammatory responses in a delayed-type hypersensitivity (DTH) mouse model.
[0281] Example 5
[0282] Single-dose study in cynomolgus monkeys
[0283] In this study, 25 µg / kg RUR was administered subcutaneously to cynomolgus monkeys (one female and one male). 20kD - IL-2 composition. Serial blood samples were taken from each animal before treatment (day -6 and day -1) and at various intervals after treatment for evaluation of Treg cell numbers and activation status by flow cytometry.
[0284] For immunophenotyping, blood samples (approximately 1.0 mL) were collected from each monkey at the following time points: before treatment (days -6 and -1), and on days 2, 3, 4, 5, 6, 7, 10, 14, and 21 after treatment. Venipuncture samples were collected into a 4% paraformaldehyde (PFA) solution containing the anticoagulant K. 2 EDTA tubes. Place tubes on wet ice awaiting transfer. Whole blood samples were analyzed by flow cytometry using the following panels and samples were analyzed for:
[0285] T cell panel: CD45 / CD3 / CD4 / CD8 / ICOS
[0286] T / B / NK group: CD45 / CD3 / CD16 / CD20
[0287] pSTAT5 group: CD3 / CD4 / CD8 / CD25 / CD127 / pSTAT5
[0288] Treg group 1: CD3 / CD4 / CD8 / CD25 / FoxP3 / Ki67
[0289] Treg group 2: CD3 / CD4 / CD8 / CD25 / FoxP3 / Helios
[0290] Computerized systems can be used for the conduct of studies, for example, flow cytometry data acquisition can use BD FACSCanto II / FACSDiva LEGENDPlex data analysis software, and flow cytometry data analysis can use DeNovo FCS Express software.
[0291] The values from males and females were averaged and the magnitude of change relative to the d-1 values is shown, marked by a dotted line. As shown in FIG9 , the number of Treg cells increased significantly after administration, reaching its maximum level 7 days after administration, and returning to near d-1 levels by day 1421. Fig.9A As shown by the hollow triangle in RUR 20kD - Nearly all Tregs induced by the IL-2 composition were proliferative, as measured by Ki67.
[0292] By administering RUR 20kD -The relative activation state of Treg stimulated by IL-2 composition is further measured by the mean fluorescence intensity (MFI) of FoxP3 and CD25.CD25 MFI reaches its maximum value on the 6th day, and then reaches stability on the 10th day, and then returns to near the pre-dose level on the 21st day.FoxP3 MFI also reaches the maximum value 6 days after administration, and then approaches to return to the pre-dose level on the 14th-21st day.In short, these data show that the discovery in mice can be converted to cynomolgus monkeys, because the Treg induction of similar amplitude in blood is seen, which is accompanied by an increase in Treg activation.However, compared with the discovery in mice, the effect in cynomolgus monkeys is naturally more persistent.
[0293] Example 6
[0294] Single-dose pharmacokinetics and toxicokinetics in mice, rats, and monkeys
[0295] OverviewRUR 20kD - Results of single-dose pharmacokinetic / toxicokinetic studies of IL-2 compositions in mice, rats and monkeys. Details of the dosing regimen are provided in Table 10.
[0296] Table 10: RUR 20kD - Overview of single-dose pharmacokinetic and toxicokinetic studies of IL-2 compositions
[0297]
[0298] For mouse studies, RUR 20kD The vehicle for the IL-2 composition was 10 mM sodium acetate, 200 mM sodium chloride, and 2% sucrose (pH 5). For rat and monkey studies, RUR 20kDThe vehicle for the IL-2 composition was 50 mM sodium acetate, 200 mM sodium chloride and 2% sucrose (pH 5).
[0299] After subcutaneous administration, RUR 20kD -IL-2 compositions are slowly absorbed in mice, rats, and monkeys, T max 0.33-1.0, 1.0-2.3 and 2.0 days respectively (Table 11). 20kD -IL-2 composition plasma exposure increased more or less dose proportionally in mice and rats. The bioavailability in rats ranged from 29.8-46.0%, and the bioavailability in monkeys was 86.2%.
[0300] In rats, RUR 20kD - The volume of distribution of the IL-2 composition at steady state (V ss ) appeared to increase with dose and ranged between 25.1 (0.01 mg / kg) and 52.6 mL / kg (1.0 mg / kg) (Table 12). Overall, in rats and monkeys, V ss 1–2 and 2–4 times larger than species-specific plasma volumes, respectively, indicating that RUR 20kD -IL-2 mainly stays in the vascular space.
[0301] The plasma clearance (CL) is very low (0.560-1.14 mL / hr / kg in rats and 0.245 mL / hr / kg in monkeys) (Table). 20kD - IL-2 composition concentrations appear to exhibit a monoexponential decay with half-lives ranging from 1.85-2.24 days in mice, 1.25-2.44 days in rats, and 10.4-12.9 days in monkeys (Tables 11 and 12 and Fig. 10A , 10B ). Expected RUR 20kD - Renal excretion of IL-2 is low due to its average molecular weight of 63 kDa, which is close to the molecular weight cutoff of the glomerular filtration membrane.
[0302] Table 11: RUR administered as a single subcutaneous dose to C57BL / 6 mice, Sprague-Dawley rats, or cynomolgus monkeys 20kD - Mean ± SE plasma pharmacokinetic / toxicokinetic parameters after IL-2 combination
[0303]
[0304] AUCinf: area under the plasma concentration-time curve from time zero to infinity;
[0305] AUClast: area under the plasma concentration-time curve from time zero to the last measurable concentration; Cmax: maximum observed plasma concentration; MRTinf: mean residence time; Tmax: time to maximum observed plasma concentration
[0306] 1. PK parameters are based on the mean of three rats at each time point.
[0307] 2. Average values for male and female monkeys.
[0308] Table 12: RUR after a single intravenous dose in Sprague-Dawley rats or cynomolgus monkeys 20kD - Mean ± SE plasma pharmacokinetic parameters after IL-2 combination
[0309]
[0310] ND: not determined; AUCinf: area under the plasma concentration-time curve from time zero to infinity; AUClast: area under the plasma concentration-time curve from time zero to the last measurable concentration; CL: clearance; MRTinf: mean residence time; Vss: apparent volume of distribution at steady state. *Average values for male and female monkeys.
[0311] Example 7
[0312] Comparative studies in mice
[0313] Studies substantially similar to those described in Example 2 were performed in which C57BL / 6 mice were administered a single subcutaneous dose of 0.03, 0.1, and 0.3 mg / kg of RUR 20kD -IL-2 composition or unmodified IL-2 (aldesleukin) at doses of 0.03 mg / kg (qddx5), 0.1 mg / kg (qdx5) and 1 mg / kg (qdx5) were administered. After administration, blood and spleen samples were collected and analyzed by flow cytometry for pharmacodynamic analysis of drug effects on lymphocyte cell populations, expressed as fold change relative to vehicle control. Results are shown in Fig. 10A and 10B Middle (RUR 20kD -IL-2 combination is labeled "RUR-IL-2" and aldesleukin is labeled "IL-2").
[0314] Example 8
[0315] RUR 20kD -Study of the efficacy of IL-2 combination in a mouse model of systemic lupus erythematosus (SLE)
[0316] This study was conducted to determine the expression of RUR using the MRL / MpJ-Faslpr mouse model, the most commonly studied mouse model of the disease. 20kD -The efficacy of IL-2 combination on the development and progression of SLE and its associated features (Perry, D., et al. , J Biomed Biotechnol 2011:271694). The MRL / MpJ-Faslpr mouse model develops an autoimmune disease that reflects the pathology of human SLE, including lymphadenopathy, elevated IgG levels, antinuclear antibody production, proteinuria, and renal failure caused by inflammation of the glomeruli. 20kD-Stock solutions of IL-2 compositions were used as test articles (1.58 mg / mL) provided in vehicle (clear liquid; 10 mM sodium acetate / 200 mM sodium chloride / 2% (w / v) sucrose), prepared in sterile water for injection (SWFI), USP; pH 5.0 ± 0.1). On the dosing day, an appropriate amount of the test article was taken out and diluted with the vehicle to achieve the desired dosing concentration (0.03 mg / kg dose and 0.3 mg / kg dose); the dose volume was 5 mL / kg. The animals used for this study were MRL / MpJ-Faslpr mice and MRL / MpJ untreated female mice, aged 6-8 weeks. The animals were randomly assigned to treatment groups. The treatment groups are described in Table 13 below. Based on the body weight and protein content levels in the urine before the start of the experiment, 45 MRL / MpJ-Faslpr mice were randomly divided into 3 groups (15 for groups 2-4). Animals in Groups 2-4 received vehicle or test articles delivered subcutaneously as described in Table 6. Group 1 -MRL / MpJ mice received vehicle as a negative control. Three (3) days after the first dose administration at Week 8, 3 mice from Groups 2-4 were humanely sacrificed, and blood samples were collected and processed. From the beginning of the study, body weight was measured twice a week, and continued throughout the process. Skin lesion photos were taken when first observed, and then taken at one-week intervals. Urine was obtained one day before dosing (at baseline), and then collected weekly thereafter. Protein levels in urine were measured using a Siemens Clinitek Status analyzer. On the day of sacrifice (3 days after the last dose at the end of the 20th week), all mice were anesthetized by intraperitoneal injection of chloral hydrate (50 mg / kg). Blood samples were collected and centrifuged at 10000 r / min for 10 min to obtain serum samples. Serum was stored at -80°C until clinical biochemistry testing. Serum samples (100 μl) were analyzed for anti-dsDNA levels by ELISA (mouse anti-dsDNA IgG-specific ELISA kit, AlphaDiagnostic International, catalog number 5120), and serum was tested for BUN concentration using a Hitachi 7020 automated biochemical analyzer. For lymphocyte analysis, blood samples were collected in EDTA-K tubes and tested for CD3 / CD4 / CD8 / Treg / NK / B cell % by flow cytometry. Results are shown in Fig.11 As indicated therein, RUR was administered at a dose of 0.3 mg / kg 20kD-IL-2 combination effectively suppressed biomarkers of renal damage (i.e., protein levels in urine) to levels close to those observed in normal mice. This study further illustrates the role of RUR-IL-2-induced Tregs in the control of physiological immune responses and disease progression in a representative animal model of SLE.
[0317] Table 13 - Treatment Groups
[0318]
[0319] a: The medium of the test article.
[0320] Example 9
[0321] RUR 20kD -Study of IL-2 combination in the antigen-dependent T cell-mediated delayed-type hypersensitivity (DTH) model
[0322] The study simulated a food allergy model (in which a high degree of allergic reaction is established) by RUR 20kD - How in vivo Treg stimulation and expansion of IL-2 compositions can downregulate T cell-mediated delayed-type hypersensitivity (DTH) responses in an antigen-dependent manner.
[0323] To develop the DTH model, Balb / c mice were treated with keyhole limpet immunoglobulin (KLI) emulsified in complete and incomplete Freund's adjuvant. Sensitization was performed by subcutaneous administration of KLH. 20kD - Subcutaneous administration of IL-2 combination (0.003, 0.01, 0.3, 0.1 or 0.3 mg / kg, q3d) or cyclosporin A (10 mg / kg, qd) was started on day 0 and continued to day 8, with intradermal challenge with KLH administered on day 5, and ear swelling was measured for four days. Immunohistochemistry (IHC) was performed on inflamed ears to quantify the percentage of FoxP3+ Treg cells after KLH challenge. After an additional 3-4 weeks, the specificity of the response was evaluated in the absence of treatment by KLH re-challenge or sensitization and challenge with the irrelevant antigen ovalbumin (OVA). In order to understand the RUR 20kD - Effect of Tregs expanded by IL-2 composition on food allergens Balb / C mice were sensitized twice a week by intraperitoneal administration of alum-emulsified OVA. Ten days after the second sensitization, mice were challenged orally with OVA eight times every other day. RUR 20kD- Subcutaneous administration of IL-2 combination (0.1 mg / kg, q3dx3) or cyclosporin A (10 mg / kg, qd) was started on day 0 and continued to day 8. The severity of the allergic response was evaluated by clinical scoring within 30-45 min after the 8th challenge. In addition, serum mast cell proteinase 1 (MCPT 1) and OVA-specific IgE titers were quantified. % Treg in peripheral blood and spleen was determined by flow cytometry.
[0324] In this mouse model of DTH, RUR 20kD - IL-2 composition administration inhibited the inflammatory response to KLH re-challenge in a dose-dependent manner. IHC analysis of inflamed ears showed significant infiltration of FoxP3+ Treg cells. The inhibitory effect on inflammation was persistent and antigen-specific, as shown by re-challenge with the same antigen 3-4 weeks later and re-challenge with an irrelevant antigen after sensitization (without further administration of RUR). 20kD -IL-2 composition). Finally, it was found that RUR 20kD - Administration of IL-2 composition is effective in reducing the symptoms of hypersensitivity reactions caused by repeated administration of the model food allergen OVA. The reduction in clinical scores of anaphylaxis was associated with a significant decrease in the levels of MCPT1 and anti-OVA-specific IgE titers and a significant increase in Tregs. RUR 20kD -IL-2 combination demonstrated antigen-specific and durable Treg expansion and therapeutic response in this KLH hypersensitivity mouse model. 20kD -IL-2 combination is effective in food allergy model. This data supports the use of RUR 20kD - IL-2 compositions are used in antigen-specific inflammation, as is the case in autoimmune and / or inflammatory diseases.
[0325] The preclinical evidence provided here supports the concept that the IL-2 conjugate Treg stimulator RUR 20kD -IL-2 compositions increase the number and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory conditions. Impaired IL-2 production and regulatory T cell dysfunction have been implicated as immune mechanisms in a variety of autoimmune diseases. Although low doses of IL-2 can be used to stimulate Tregs to obtain clinical benefit, poor pharmacokinetics require daily delivery, adverse events are dose limiting, and Treg increases are modest and short-lived. RUR 20kD -IL-2 compositions provide IL-2 conjugate Treg stimulators intended for low-dose subcutaneous administration to selectively restore Treg homeostasis with minimal impact on conventional T cell function. 20kD- The ability of IL-2 compositions to selectively expand the number and activity of Tregs in mouse and non-human primate models and to assess RUR 20kD -Data on the efficacy of IL-2 compositions in autoimmune models. Affinity for the IL-2 receptor was evaluated by surface plasmon resonance. Activity in human PBMCs can be measured by pSTAT5 induction in multiple lymphocyte populations using flow cytometry and time-of-flight mass cytometry (CyToF). In vivo activity after subcutaneous administration in C57BL / 6 mice or cynomolgus monkeys was measured by flow cytometry by changes in lymphocyte number and activation. Ex vivo Treg function was determined by inhibition of Tcon proliferation by isolated splenic Tregs. Efficacy was evaluated in a model of systemic lupus erythematosus (SLE) using MRL / MpJ-Faslpr mice. RUR relative to IL-2Rα and IL-2Rαβ complexes 20kD -IL-2 compositions have a greatly reduced affinity for human IL-2Rβ, indicating preferential activation of Tregs expressing high-affinity IL-2Rαβγ over Tcon expressing low-affinity IL-2Rβγ. 20kD -The IL-2 combination stimulated more sensitively, showing increases in STAT5 phosphorylation relative to other lymphocyte subsets in human PBMCs. In mice, a single administration resulted in Treg mobilization in the blood and spleen that lasted 7-10 days without Tcon activation, an effect consistent with the induction of Treg activation markers and increased ex vivo suppressive capacity. In cynomolgus monkeys, plasma exposure was more prolonged compared to an equivalent total dose of rhIL-2 administered daily for five days, with Treg mobilization and activity persisting for more than 14 days after a single administration – a superior response in magnitude, duration, and specificity. Finally, RUR 20kD -IL-2 combination is effective in a mouse model of SLE. In the SLE model, repeated administration of RUR over 12 weeks 20kD -IL-2 combination maintained elevated Tregs, reduced blood urea nitrogen, and restored urine protein levels and renal histopathology to normal. 20kD - Repeated administration of the IL-2 combination increased Tregs and decreased germinal center B cells in the spleen and reversed lung dysfunction. RUR 20kD - IL-2 compositions provide sustained, preferential activation of Tregs and demonstrate efficacy in SLE model systems.
[0326] Example 10
[0327] A phase I, double-blind, randomized, placebo-controlled study to evaluate RUR in healthy volunteers 20kD- Safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending subcutaneous doses of an IL-2 composition
[0328] A double-blind, randomized, placebo-controlled study was conducted to evaluate the RUR of single ascending low subcutaneous doses of 20kD -IL-2 composition (RUR 20kD The study was divided into seven groups, in which subjects received 0.3, 1.0, 3.0, 6.0, 9.0, 13.5, or 20.0 µg / kg RUR 20kD -IL-2. Twelve subjects were randomized to each dose group, nine of whom received a single subcutaneous dose of RUR 20kD -IL-2, and three received placebo. 20kD -IL-2 is formulated as a sterile liquid for subcutaneous injection, which is diluted with sterile 0.9% sodium chloride solution. The drug product is provided in single-use glass vials and stored at 2-8°C. Each vial of drug product contains 0.75±0.1 mg of rhIL-2 (based on RUR 20kD -IL-2). 20kD -IL-2 was formulated in 10 mM sodium acetate, 150 mM sodium chloride, 2% (w / v) sucrose, pH 5.0, at a concentration of approximately 1.0 mg / mL protein. Placebo was a commercially available 0.9% sodium chloride solution. The starting dose of 0.3 μg / kg was selected using the lowest anticipated biological effect level (MABEL) approach and supported by the no observed adverse effect level (NOAEL) in the most sensitive species from nonclinical toxicology studies. The starting dose was set at 0.3 µg / kg to allow for the assessment of RUR 20kD -IL-2 pharmacokinetics and safety. 20kD -IL-2 and one received placebo) were administered in a double-blind manner and monitored for possible side effects for a period of at least 7 days prior to the start of the study.
[0329] The primary objective of the study was to evaluate the RUR of 20kD - Safety and tolerability of IL-2. The secondary objectives of this study are to (1) observe the time course and extent of changes in the number and / or activity of regulatory T cells (Tregs), and (2) characterize the RUR of IL-2 administered as a single subcutaneous dose. 20kD - IL-2 pharmacokinetic (PK) profile, and (3) evaluation of RUR 20kD- Immunological effects of IL-2 in the blood, including effects on cytokines, T cells, other peripheral blood populations, other serum proteins, changes in gene expression, and anti-drug antibodies. In the first phase of the study, immune markers were tested before dosing and until 20 hours after dosing. Specifically, in the RUR 20kD - Treg, CD4 + -T cells, CD8 + - T cells, natural killer (NK) cells, cytokines, soluble CD25 and RNA. In the follow-up period, the same immune markers were also tested at 4-, 5-, 6-, 7-, 8-, 10-, 12-, 15-, 18-, 20-, 25-, 30-, 40 and 50-days after dosing.
[0330] No dose-limiting toxicities (DLTs), serious adverse events (SAEs), deaths, or clinically apparent abnormalities were reported. Adverse events (AEs) were limited to mild (grade 1) injection site reactions, and no evidence of AEs known to be associated with high-dose IL-2 was observed.
[0331] Preliminary PK analysis showed that in most subjects, RUR 20kD -IL-2 reaches a maximum concentration approximately 4-6 days after administration, and the concentration hardly changes until approximately 2 weeks after administration, after which the concentration decreases, with a half-life of approximately 8-9 days.
[0332] Pharmacodynamic (PD) evaluation reveals RUR 20kD -IL-2 leads to circulating CD4+FoxP3+CD25 亮 In the 3.0, 6.0, 9.0, 13.5 and 20.0 μg / kg single-dose groups, circulating CD4+FoxP3+CD25 亮 The absolute number of Tregs continued to increase, with levels not returning to baseline until approximately 20 to 25 days after administration. At 3.0, 6.0, 9.0, 13.5, and 20.0 μg / kg doses, CD4+FoxP3+CD25 亮 The number of Tregs increased by an average of 3-fold, 3.5-fold, 4.1-fold, 5-fold, and 8.1-fold, respectively. The total CD4+FoxP3+CD25+Treg population also increased at doses of 3.0, 6.0, 9.0, 13.5, and 20.0 μg / kg, but the magnitude of change was less than that for CD4+FoxP3+CD25 亮 At 0.3 and 1.0 μg / kg, RUR was significantly higher than that of subjects receiving placebo. 20kD- The number of Tregs in IL-2 treated subjects was not changed compared to placebo subjects. See RUR 20kD - The main effect of IL-2 on Tregs, because at any dose, RUR 20kD - No changes in the percentage or number of T cell populations (CD4+, CD8+) were observed with IL-2. Smaller increases in the percentage and absolute number of NK cells were observed at 13.5 and 20.0 μg / kg, with no evidence of AEs associated with high-dose IL-2.
[0333] like Fig.12 As shown in 20kD -IL-2 combination resulted in a dose-dependent increase in CD4+FoxP3+CD25 bright Tregs. At 3.0, 6.0, 9.0 and 13.5 μg / kg, the absolute number of CD4+FoxP3+CD25 bright Tregs continued to increase, with levels not returning to baseline until 20-25 days after administration. At doses of 3.0, 6.0, 9.0 and 13.5 μg / kg, the number of CD4+FoxP3+CD25 bright Tregs increased by an average of 3.0-fold, 3.5-fold, 4.1-fold and 5.0-fold, respectively, compared with placebo, with the maximum response shifting from a peak at 84 hours at 3.0 μg / kg to a more prolonged peak response lasting 7 to 12 days at 13.5 μg / kg, and then returning to baseline levels by days 20-25. As Fig.13 As shown in Figure 2, there was also a dose-dependent increase in the total CD4+FoxP3+CD25+ Treg population at 3.0, 6.0, 9.0, and 13.5 μg / kg, but the magnitude of the change was less than that observed for CD4+FoxP3+CD25+ Treg. No RUR was observed at 0.3 μg / kg and 1 μg / kg. 20kD -Change in total CD4+ Tregs in IL-2 treated subjects compared to placebo subjects ( Fig.13 ).
[0334] Importantly, see RUR 20kD -The main effect of IL-2 on Tregs, because in RUR 20kD -No changes in the percentage of Tcon cell population (CD4+, CD8+) were observed in subjects treated with IL-2 or placebo. However, at 13.5 μg / kg, there was a significant difference in the percentage of Tcon cell population (CD4+, CD8+) in the RUR 20kD A small increase in the absolute number of CD8+ T cells and the percentage of Ki67+ CD8+ T cells was observed in the -IL-2 subjects (Figure 14A-D). The absolute number of CD4+ T cells did not change at any dose level.
[0335] The CD56+ NK cell population was also analyzed. An increase in the absolute number of circulating NK cells was noted, with a smaller increase in the percentage of this cell subset at the 13.5 μg / kg dose level, but not at lower dose levels. In addition, a dose-dependent increase in the percentage of CD56+ NK cells expressing Ki67 (a marker of proliferation and, therefore, activation) was also noted at 3.0, 6.0, 9.0, and 13.5 μg / kg. At 3.0, 6.0, and 9.0 μg / kg, there was an increase in the percentage of CD56+ NK cells after administration of RUR 20kD After IL-2 administration, the percentage of Ki67 expression was approximately 10%, 20-30%, and 30-40%, respectively. At a dose of 13.5 μg / kg, the percentage of Ki67 expression did not increase further and remained at 30-40%.
[0336] RUR according to SAD study 20kD -IL-2 treatment resulted in a sustained increase in the number of CD4+FoxP3+CD25bright Tregs, with levels not returning to baseline until 20-25 days after administration. The total CD4+FoxP3+CD25+ Treg population also increased, although the magnitude of the change was less than that observed for CD4+FoxP3+CD25bright Tregs. Increased numbers of CD8+ T cells and NK cells were observed at 13.5 μg / kg.
[0337] Also calculates RUR 20kD -IL-2, 20.0 mg / kg (n=13); placebo (n=3), and RUR 20kD - Additional cohorts of IL-2, 28.0 mg / kg (n=9); placebo (n=3). Each cohort was followed for 50 days to evaluate the RUR of single ascending doses of s.c. in healthy volunteers 20kD - The effect of IL-2 on safety and tolerability in subjects, as assessed by adverse events, vital signs, and clinical laboratory evaluations, as well as the time course and extent of changes in the number and activity of Treg, Tcon, and NK cells and subsets, RUR 20kD - The pharmacokinetics and other immunological effects of IL-2, such as cytokine levels, peripheral blood cell populations, serum proteins and gene expression were assessed.
[0338] In general, safety results found no dose-limiting toxicities, deaths, or adverse events leading to study discontinuation, and no clinically significant vital sign, ECG, or physical examination abnormalities. Adverse events were primarily limited to mild or moderate (grade 1 or 2) injection site reactions, 4 subjects experienced grade 1 headache events, 1 subject at the highest dose tested (28.0 µg / kg) experienced mild (grade 1) signs and symptoms of fever, anorexia, vomiting, diarrhea, tachycardia, and myalgia (all grade 1 in severity) that were attributed to elevated cytokine levels, and no anti-drug antibodies were induced.
[0339] Typically, it is observed that in response to RUR 20kD -IL-2 sustained dose-dependent increase in CD25-bright Tregs (see Figure 15). 20kD When the IL-2 combination was used, a 17-fold average peak increase in the number of CD25-bright Tregs above pre-dose values was observed. Treg levels peaked on days 10-12 and did not return to baseline until 20-25 days after administration. > At 13.5 µg / kg, increases in Treg activation markers ICOS and CTLA4 were observed.
[0340] No substantial changes were observed in the percentage of Tcon cells, and CD56+ NK cells were observed in response to RUR 20kD - Minimal increase in IL-2 (see Figure 16). (CD16+CD56+ NK cells were also enumerated, data not shown). The increase in NK cells was not dose-dependent. At the highest concentration of RUR 20kD -IL-2, a 2-fold increase in NK cells was observed. 20kD -IL-2 induced a dose-dependent increase in Tregs, but not CD8+ T cells, up to 28 µg / kg. At 28 µg / kg, RUR 20kD - IL-2 administration resulted in a 15-fold increase in mean peak Treg:CD8 compared to baseline (see Figure 17).
[0341] Research Objective Rating (RUR) 20kD-The safety and tolerability of IL-2 in humans administered single ascending doses subcutaneously (SC). In addition, the time course and extent of changes in the number and percentage of Tregs, conventional CD4+ and CD8+ T cells, NK cells in peripheral blood, cytokine levels and pharmacokinetics (PK) were investigated. In this first-in-human, double-blind, single ascending dose study, healthy volunteers received SC doses ranging from 0.3 to 28 ug / kg (9 active agents: 3 placebos per group), and subjects were followed for 50 days. All 8 planned groups completed dosing. There were no dose-limiting toxicities, serious adverse events, deaths, or clinically apparent abnormalities in vital signs, electrocardiograms, or laboratory test values. Attributed to RUR 20kD - Adverse events for IL-2 were primarily limited to mild (grade 1) injection site reactions. One subject at the highest dose tested demonstrated transient and mild (grade 1) symptoms of elevated cytokine levels and lymphopenia, which resolved without treatment. No other individuals at any dose level had systemic signs or symptoms known to be related to IL-2 therapy. To date, the first 6 cohorts have been tested for anti-drug antibodies, and none were detected. RUR 20kD -IL-2 reaches maximum plasma levels 4-6 days after administration, remains virtually unchanged for ~2 weeks, and then declines with a half-life of ~8-9 days. See RUR 20kD -The main effect of IL-2 on Treg. In the 3.0 to 28.0 ug / kg dose group, a dose-dependent and sustained increase in the absolute number and percentage of circulating CD4+FoxP3+CD25 bright Tregs was observed. The elevated levels peaked on days 10-12 and did not return to baseline until ~20 to 25 days after administration. At 28.0 ug / kg, the average peak increase in the number of these CD25 bright Tregs was 17 times higher than the baseline, and the average peak percentage increased from 0.5% to 7.4%. In addition, at doses of ≥13.5ug / kg, Treg activation markers increased. At the highest dose tested, the percentage and number of NK cells increased by an average of 3.5-fold, but no changes in the percentage or number of conventional CD4+ or CD8+ T cells were observed. RUR 20kD -IL-2 combination selectively induced Tregs, as evidenced by a 15-fold increase in the mean peak Treg:CD8 ratio over baseline in the 28.0 ug / kg group. In summary, a single dose of the IL-2 conjugate T-reg stimulator RUR 20kD -IL-2 was well tolerated and safe. RUR 20kD-IL-2 resulted in a significant and selective dose-dependent increase in circulating CD25-bright Tregs, with minimal effects on conventional T cells and relatively little effect on NK cells. These clinical results extend previous studies showing that RUR 20kD - Animal studies of the persistent and Treg-selective effects of IL-2 and for testing RUR 20kD -IL-2 has gained strong support as a new therapeutic agent for autoimmune diseases such as systemic lupus.
[0342] RUR 20kD -IL-2 combination was safe and well tolerated in this first-in-human single ascending dose study and resulted in a significant and selective dose-dependent increase in circulating CD25-bright Treg cells. There was minimal effect on Tcon and NK cells, and the study data provide a promising approach to testing RUR in autoimmune and inflammatory diseases 20kD -IL-2 provided support.
[0343] Embodiment 11
[0344] A phase I, double-blind, randomized, placebo-controlled, ascending-dose study to evaluate subcutaneous RUR 20kD - Safety, tolerability, pharmacokinetics, and pharmacodynamics of IL-2 in patients with systemic lupus erythematosus
[0345] A double-blind, randomized, placebo-controlled study was conducted to evaluate the RUR of escalating doses of 4 dose cohorts in patients with minimal to moderate systemic lupus erythematosus (SLE). 20kD The safety, tolerability, PK and immunological effects of RUR-IL-2 were evaluated. The effect on SLE disease activity was also evaluated. Twelve SLE patients with minimal to moderate disease activity were randomized into each of four dose groups, nine of whom received multiple subcutaneous doses of RUR-IL-2-20kD in a 1.0 mg / mL aqueous solution and three received a placebo. RUR was prepared as described herein, for example, as described in Example 1-A. 20kD -IL-2 drugs and placebo. Active clinical SLE disease activity was not required as an inclusion criterion. In cohort 1, a starting dose of 3.0 μg / kg was administered 3 times at two-week intervals (days 1, 15, and 29). This starting dose was based on the RUR of a single subcutaneous dose previously determined in the above study. 20kD- A favorable safety and PD profile of IL-2. Subsequent dose levels in Cohorts 2, 3, and 4 were up to twice the dose level of the previous dose cohort, respectively. Patients in Cohorts 1-3 received three doses of study drug at two-week intervals for a total of four weeks. The dose range to be evaluated during the study was 3.0 μg / kg to 24 μg / kg. Patients in Cohort 4 received RUR administered on Days 1, 15, 29, 43, 57, 71, and 85. 20kD - IL-2 treatment for twelve weeks. This group provides information on the safety of administration and the 20kD - Data on the PK and PD profiles of IL-2 over a longer duration of treatment. 20kD After 1-IL-2 or placebo, patients were followed for an additional 50 days to assess safety, PK, PD, and preliminary efficacy. The Safety Review Committee evaluated eight of the twelve subjects in each cohort for possible safety issues two weeks after the third dose of the last patient. In addition, the Safety Review Committee evaluated all patients in Cohort 4 twice: (1) two weeks after the first eight subjects received their third dose, and (2) two weeks after all subjects received all doses of study drug. In addition to safety findings, immunological changes, including Treg, CD4 + -T cells, CD8 + -T cell and NK cell responses, cytokine levels, and available PK data to determine dose levels. The primary objective of the study is to evaluate the RUR of 100 mg / dL administered as multiple ascending subcutaneous doses to patients with SLE 20kD - Safety and tolerability of IL-2. The secondary objectives of this study are to (1) characterize the RUR after multiple subcutaneous dosing in patients with SLE 20kD -PK profile of IL-2, (2) Evaluation of RUR 20kD - Effect of IL-2 on PD biomarkers (including Treg and Treg subsets, CD4 + -T cells, CD8 + -T cells, NK cell number and function, and cytokine levels) of the time course and extent of changes, (3) to evaluate RUR 20kD - The effect of IL-2 on the presence and levels of antibodies against double-stranded DNA and the levels of complement C3 and C4 in patients with SLE, and (4) Evaluation of RUR 20kD - Effect of IL-2 on disease activity in SLE patients. In Table 14 below, the results depicting the preliminary PK data from the ascending dose study are compared with the data from the single subcutaneous study:
[0346] Table 14. PK data in single-dose and multiple-dose human studies
[0347]
Claims
1. A composition comprising a PEGylated IL-2 conjugate of the formula: in: IL-2 is interleukin-2; n is independently at each occurrence an integer from 3 to 4000; and n' is 1 and 2 and 3; and wherein, on a molar basis, the composition comprises 5 mol% or less of mono-PEGylated IL-2 conjugates where n' is equal to 1, 28 mol% to 60 mol% of di-PEGylated IL-2 conjugates where n' is equal to 2, and 24 mol% to 65 mol% of tri-PEGylated IL-2 conjugates where n' is equal to 3, and wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons.
2. The composition of claim 1, wherein the IL-2 is aldesleukin.
3. The composition of any one of the preceding claims, wherein the composition comprises no more than 10 mol% of a PEGylated IL-2 conjugate encompassed by the formula when considered together wherein n' is selected from 1, 4, 5, or an integer greater than 5.
4. The composition of claim 3, comprising no more than 10 mol% of the PEGylated IL-2 conjugate with n' equal to 4.
5. The composition of claim 3, comprising no more than 7 mol% of the PEGylated IL-2 conjugate with n' equal to 4.
6. The composition of claim 3, comprising no more than 5 mol% of the PEGylated IL-2 conjugate with n' equal to 4.
7. The composition comprising a mixture of PEGylated IL-2 conjugates according to claim 1 or 2, wherein the composition comprises approximately equimolar amounts of the PEGylated IL-2 conjugates of formula (II) and formula (III):
8. The composition comprising a mixture of PEGylated IL-2 conjugates according to claim 1 or 2, wherein the composition comprises a PEGylated IL-2 conjugate having the formula: The molar ratio of the PEGylated IL-2 conjugate of formula (II) / formula (III) is 1.4:1; 1.3:1; 1.2:1; 1.1:1; 1:1; 1:1.1; 1:1.2; 1:1.3; and 1:1.
4.
9. The composition of claim 2, wherein each branched polyethylene glycol portion of aldesleukin The average number is 2; 2.1; 2.2; 2.3; 2.4; 2.5; 2.6; 2.6; 2.7; 2.8; 2.9; or 3.
10. The composition of claim 9, wherein the average number of branched polyethylene glycol moieties per aldesleukin is about 2.
5.
11. The composition of claim 1 or 2, wherein the average value of n is about 226.
12. The composition of claim 1 or 2, further comprising 80% or more of the combined di-PEGylated and tri-PEGylated IL-2 conjugates.
13. The composition of claim 1 or 2, comprising, on a molar basis, 2.5 to 4.5 mol% of mono-PEGylated IL-2 conjugates, and 35 to 50 mol% of di-PEGylated IL-2 conjugates, and 38 to 46 mol% of tri-PEGylated IL-2 conjugates, and 3 to 10 mol% of higher PEGylated IL-2 conjugates, and wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons.
14. The composition of claim 13, further comprising 80 to 95 mol% of the combined total amount of di-PEGylated and tri-PEGylated IL-2 conjugates.
15. The composition of claim 1 or 2, comprising, on a molar basis, 2.8 to 3.8 mol% of mono-PEGylated IL-2 conjugates, and 44 to 48 mol% of di-PEGylated IL-2 conjugates, and 41 to 44 mol% of tri-PEGylated IL-2 conjugates, and 7 to 9 mol% of higher PEGylated IL-2 conjugates, and wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons.
16. The composition of claim 15, further comprising 87 to 90 mol% of the combined total amount of di-PEGylated and tri-PEGylated IL-2 conjugates.
17. The composition of claim 1 or 2, comprising, on a molar basis, 2.8 to 3.8 mol% of mono-PEGylated IL-2 conjugates, and 44 to 48 mol% of di-PEGylated IL-2 conjugates, and 41 to 44 mol% of tri-PEGylated IL-2 conjugates, and 7 to 9 mol% of higher PEGylated IL-2 conjugates, and wherein the composition comprises a mixture of mono-PEGylated IL-2 conjugates having a PEG moiety attached at one of lysines K7 or K8 or K31 or K75, and wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons.
18. The composition of claim 17, further comprising 87 to 90 mol% of the combined total amount of di-PEGylated and tri-PEGylated IL-2 conjugates.
19. The composition of claim 1 or claim 2, comprising, on a molar basis, 2.8 to 3.8 mol% of a mono-PEGylated IL-2 conjugate, and 44 to 48 mol% of a di-PEGylated IL-2 conjugate, and 41 to 44 mol% of a tri-PEGylated IL-2 conjugate, and 7 to 9 mol% of a higher PEGylated IL-2 conjugate, and wherein the composition comprises a mono-PEGylated IL-2 conjugate having a PEG moiety attached at lysine K7, wherein the nominal average molecular weight of each branched polyethylene glycol moiety is about 20,000 Daltons.
20. The composition of claim 19, further comprising 87 to 90 mol% of the combined total amount of di-PEGylated and tri-PEGylated IL-2 conjugates.
21. The composition of claim 1 or 2, further comprising a pharmaceutically acceptable excipient.
22. The composition of claim 1 or 2 in a form suitable for parenteral administration.
23. The composition of claim 1 or 2 in a form suitable for subcutaneous administration.
24. The composition of claim 21 comprising an aqueous diluent.
25. The composition of claim 24 having a pH of about 5.
26. The composition of claim 25, further comprising sodium acetate, sodium chloride, and sucrose.
27. The composition of claim 22, comprising 1.5 mg / ml protein equivalent, 10 mM sodium acetate, 110 mM sodium chloride, 2 w / v% sucrose, pH 5.
0.
28. A composition according to claim 1 or 2 for use in therapy.
29. The composition of claim 1 or 2, for use in a method of increasing the ratio of regulatory T cells to effector T cells in a subject.
30. The composition for use according to claim 29, wherein the regulatory T cells are selected from Foxp3+ and CD25+ cells.
31. The composition for use according to claim 29, wherein the effector T cells are selected from CD4+ and CD8+ cells.
32. The composition for use according to claim 29, wherein the fold increase in regulatory T cells reaches a value of at least 2 when compared to baseline when assessed in an in vivo mouse model.
33. The composition for use according to claim 29, wherein the fold increase in regulatory T cells reaches a value of at least 4 when compared to baseline when assessed in an in vivo mouse model.
34. The composition for use according to claim 29, wherein the increase in the number of regulatory T cells is maintained above baseline levels for at least 3 days after administration.
35. The composition for use according to claim 29, wherein the increase in the number of regulatory T cells is maintained above baseline levels for at least 5 days after administration.
36. The composition of claim 1 or 2, for use in treating an autoimmune disease.
37. A composition for use according to claim 36, wherein the composition is administered by subcutaneous injection.
38. The composition for use according to claim 36, wherein the composition is administered once every 2 weeks or once every 4 weeks.
39. The composition for use according to claim 36, wherein the composition is administered once every two weeks at a dose of between 3-24 μg / kg.
40. A composition for use according to claim 36, wherein the autoimmune disease is systemic lupus erythematosus.
41. A composition for use according to claim 36, wherein the autoimmune disease is atopic dermatitis.
42. A composition for use according to claim 36, wherein the autoimmune disease is ulcerative colitis or Crohn's disease.
43. The composition of claim 1 or 2 for use in the treatment of allergic diseases.
Citation Information
Patent Citations
Photoprotective cosmetic compositions containing aromatic amide, sulphonamide or carbamate derivatives of acrylonitrile and novel aromatic amide, sulphonamide or carbamate derivatives of acrylonitrile
US20040175337A1
Mutant Interleukin-2 (IL-2) Polypeptides
US20100036097A1
Process for preparing human interleukin 2
US4401756A
Oxidation-resistant muteins of Il-2 and other protein
US5116943A
IL-2 analogs containing N-linked glycosylation sites
US5153310A
Cited By
Site-specific coupled pegylated interleukin-2 mutant with receptor affinity preference and use thereof
EP4631972A1
Site-specific coupled pegylated interleukin-2 mutant with receptor affinity preference and use thereof
WO2024103860A1
